<html data-n-head-ssr="" lang="en" data-n-head="%7B%22lang%22:%7B%22ssr%22:%22en%22%7D%7D"><head> <title>Radius Health, Inc. ‚Äì RDUS Q4 2017 Earnings Call Transcript</title><meta data-n-head="ssr" charset="utf-8"><meta data-n-head="ssr" name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0"><meta data-n-head="ssr" data-hid="keywords" name="keywords" content="stock analysis, fundamental analysis, financial analysis, alternative data, stock screener"><meta data-n-head="ssr" data-hid="og:image" property="og:image" content="https://strike.market/images/imageFacebook.png"><meta data-n-head="ssr" data-hid="og:type" property="og:type" content="website"><meta data-n-head="ssr" data-hid="og:site_name" property="og:site_name" content="Strike.Market"><meta data-n-head="ssr" data-hid="twitter:card" name="twitter:card" content="summary"><meta data-n-head="ssr" data-hid="twitter:site" name="twitter:site" content="@strike_market"><meta data-n-head="ssr" data-hid="twitter:image" name="twitter:image" content="https://strike.market/images/imageTwitter.png"><meta data-n-head="ssr" name="format-detection" content="telephone=no"><meta data-n-head="ssr" data-hid="charset" charset="utf-8"><meta data-n-head="ssr" data-hid="mobile-web-app-capable" name="mobile-web-app-capable" content="yes"><meta data-n-head="ssr" data-hid="apple-mobile-web-app-capable" name="apple-mobile-web-app-capable" content="yes"><meta data-n-head="ssr" data-hid="apple-mobile-web-app-status-bar-style" name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta data-n-head="ssr" data-hid="apple-mobile-web-app-title" name="apple-mobile-web-app-title" content="Strike.Market"><meta data-n-head="ssr" data-hid="theme-color" name="theme-color" content="#1b2245"><meta data-n-head="ssr" data-hid="og:image:width" name="og:image:width" property="og:image:width" content="512"><meta data-n-head="ssr" data-hid="og:image:height" name="og:image:height" property="og:image:height" content="512"><meta data-n-head="ssr" data-hid="og:image:type" name="og:image:type" property="og:image:type" content="image/png"><meta data-n-head="ssr" data-hid="description" name="description" content="Radius Health, Inc. (RDUS) full earning call transcript from 2 Mar 2018."><meta data-n-head="ssr" data-hid="og:title" property="og:title" content="Radius Health, Inc. ‚Äì RDUS Q4 2017 Earnings Call Transcript"><meta data-n-head="ssr" data-hid="og:description" property="og:description" content="Radius Health, Inc. (RDUS) full earning call transcript from 2 Mar 2018."><meta data-n-head="ssr" data-hid="og:url" property="og:url" content="https://strike.market/stocks/RDUS/earnings-call-transcripts/56392"><meta data-n-head="ssr" data-hid="twitter:title" name="twitter:site" content="Radius Health, Inc. ‚Äì RDUS Q4 2017 Earnings Call Transcript"><meta data-n-head="ssr" data-hid="twitter:description" name="twitter:description" content="Radius Health, Inc. (RDUS) full earning call transcript from 2 Mar 2018."><link data-n-head="ssr" rel="preconnect" href="//d3pvdr4j0h358p.cloudfront.net"><link data-n-head="ssr" data-hid="shortcut-icon" rel="shortcut icon" href="https://d3pvdr4j0h358p.cloudfront.net/icons/icon_64x64.628f36.png"><link data-n-head="ssr" data-hid="apple-touch-icon" rel="apple-touch-icon" href="https://d3pvdr4j0h358p.cloudfront.net/icons/icon_512x512.628f36.png" sizes="512x512"><link data-n-head="ssr" href="https://d3pvdr4j0h358p.cloudfront.net/icons/splash_iphonese_640x1136.628f36.png" media="(device-width: 320px) and (device-height: 568px) and (-webkit-device-pixel-ratio: 2)" rel="apple-touch-startup-image" data-hid="apple-touch-startup-image-iphonese"><link data-n-head="ssr" href="https://d3pvdr4j0h358p.cloudfront.net/icons/splash_iphone6_50x1334.628f36.png" media="(device-width: 375px) and (device-height: 667px) and (-webkit-device-pixel-ratio: 2)" rel="apple-touch-startup-image" data-hid="apple-touch-startup-image-iphone6"><link data-n-head="ssr" href="https://d3pvdr4j0h358p.cloudfront.net/icons/splash_iphoneplus_1080x1920.628f36.png" media="(device-width: 621px) and (device-height: 1104px) and (-webkit-device-pixel-ratio: 3)" rel="apple-touch-startup-image" data-hid="apple-touch-startup-image-iphoneplus"><link data-n-head="ssr" href="https://d3pvdr4j0h358p.cloudfront.net/icons/splash_iphonex_1125x2436.628f36.png" media="(device-width: 375px) and (device-height: 812px) and (-webkit-device-pixel-ratio: 3)" rel="apple-touch-startup-image" data-hid="apple-touch-startup-image-iphonex"><link data-n-head="ssr" href="https://d3pvdr4j0h358p.cloudfront.net/icons/splash_iphonexr_828x1792.628f36.png" media="(device-width: 414px) and (device-height: 896px) and (-webkit-device-pixel-ratio: 2)" rel="apple-touch-startup-image" data-hid="apple-touch-startup-image-iphonexr"><link data-n-head="ssr" href="https://d3pvdr4j0h358p.cloudfront.net/icons/splash_iphonexsmax_1242x2688.628f36.png" media="(device-width: 414px) and (device-height: 896px) and (-webkit-device-pixel-ratio: 3)" rel="apple-touch-startup-image" data-hid="apple-touch-startup-image-iphonexsmax"><link data-n-head="ssr" href="https://d3pvdr4j0h358p.cloudfront.net/icons/splash_ipad_1536x2048.628f36.png" media="(device-width: 768px) and (device-height: 1024px) and (-webkit-device-pixel-ratio: 2)" rel="apple-touch-startup-image" data-hid="apple-touch-startup-image-ipad"><link data-n-head="ssr" media="(device-width: 834px) and (device-height: 1112px) and (-webkit-device-pixel-ratio: 2)" rel="apple-touch-startup-image" data-hid="apple-touch-startup-image-ipadpro1"><link data-n-head="ssr" media="(device-width: 834px) and (device-height: 1194px) and (-webkit-device-pixel-ratio: 2)" rel="apple-touch-startup-image" data-hid="apple-touch-startup-image-ipadpro2"><link data-n-head="ssr" media="(device-width: 1024px) and (device-height: 1366px) and (-webkit-device-pixel-ratio: 2)" rel="apple-touch-startup-image" data-hid="apple-touch-startup-image-ipadpro3"><link data-n-head="ssr" rel="manifest" href="https://d3pvdr4j0h358p.cloudfront.net/manifest.2e8226ab.json" data-hid="manifest"><link data-n-head="ssr" rel="canonical" href="https://strike.market/stocks/RDUS/earnings-call-transcripts/56392"><script src="https://pagead2.googlesyndication.com/pagead/managed/js/adsense/m202310040101/reactive_library_fy2021.js?bust=31078558"></script><script src="https://partner.googleadservices.com/gampad/cookie.js?domain=strike.market&amp;callback=_gfp_s_&amp;client=ca-pub-9608158334186947&amp;cookie=ID%3D951edeb35ac1ddb1-22b541b182e400d2%3AT%3D1696806510%3ART%3D1696806511%3AS%3DALNI_Mbsinxii4ztjEisqVtABUrkshuwpA&amp;gpic=UID%3D00000d97d3596ecf%3AT%3D1696806510%3ART%3D1696806510%3AS%3DALNI_Mbqse9HQzvxL9l27akHLJS_qd4m8Q"></script><script src="https://pagead2.googlesyndication.com/pagead/managed/js/adsense/m202310040101/show_ads_impl_fy2021.js?bust=31078558" id="google_shimpl"></script><script data-n-head="ssr" src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-9608158334186947" defer="" data-checked-head="true"></script><link rel="preload" href="https://d3pvdr4j0h358p.cloudfront.net/6cab9b3.js" as="script"><link rel="preload" href="https://d3pvdr4j0h358p.cloudfront.net/6cec9d8.js" as="script"><link rel="preload" href="https://d3pvdr4j0h358p.cloudfront.net/css/550030c.css" as="style"><link rel="preload" href="https://d3pvdr4j0h358p.cloudfront.net/1eb99f0.js" as="script"><link rel="preload" href="https://d3pvdr4j0h358p.cloudfront.net/0e1da10.js" as="script"><link rel="stylesheet" href="https://d3pvdr4j0h358p.cloudfront.net/css/550030c.css"> <meta http-equiv="origin-trial" content="A7CQXglZzTrThjGTBEn1rWTxHOEtkWivwzgea+NjyardrwlieSjVuyG44PkYgIPGs8Q9svD8sF3Yedn0BBBjXAkAAACFeyJvcmlnaW4iOiJodHRwczovL2RvdWJsZWNsaWNrLm5ldDo0NDMiLCJmZWF0dXJlIjoiUHJpdmFjeVNhbmRib3hBZHNBUElzIiwiZXhwaXJ5IjoxNjk1MTY3OTk5LCJpc1N1YmRvbWFpbiI6dHJ1ZSwiaXNUaGlyZFBhcnR5Ijp0cnVlfQ=="><meta http-equiv="origin-trial" content="A3vKT9yxRPjmXN3DpIiz58f5JykcWHjUo/W7hvmtjgh9jPpQgem9VbADiNovG8NkO6mRmk70Kex8/KUqAYWVWAEAAACLeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXN5bmRpY2F0aW9uLmNvbTo0NDMiLCJmZWF0dXJlIjoiUHJpdmFjeVNhbmRib3hBZHNBUElzIiwiZXhwaXJ5IjoxNjk1MTY3OTk5LCJpc1N1YmRvbWFpbiI6dHJ1ZSwiaXNUaGlyZFBhcnR5Ijp0cnVlfQ=="><meta http-equiv="origin-trial" content="A4A26Ymj79UVY7C7JGUS4BG1s7MdcDokAQf/RP0paks+RoTYbXHxceT/5L4iKcsleFCngi75YfNRGW2+SpVv1ggAAACLeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXRhZ3NlcnZpY2VzLmNvbTo0NDMiLCJmZWF0dXJlIjoiUHJpdmFjeVNhbmRib3hBZHNBUElzIiwiZXhwaXJ5IjoxNjk1MTY3OTk5LCJpc1N1YmRvbWFpbiI6dHJ1ZSwiaXNUaGlyZFBhcnR5Ijp0cnVlfQ=="><meta http-equiv="origin-trial" content="As0hBNJ8h++fNYlkq8cTye2qDLyom8NddByiVytXGGD0YVE+2CEuTCpqXMDxdhOMILKoaiaYifwEvCRlJ/9GcQ8AAAB8eyJvcmlnaW4iOiJodHRwczovL2RvdWJsZWNsaWNrLm5ldDo0NDMiLCJmZWF0dXJlIjoiV2ViVmlld1hSZXF1ZXN0ZWRXaXRoRGVwcmVjYXRpb24iLCJleHBpcnkiOjE3MTk1MzI3OTksImlzU3ViZG9tYWluIjp0cnVlfQ=="><meta http-equiv="origin-trial" content="AgRYsXo24ypxC89CJanC+JgEmraCCBebKl8ZmG7Tj5oJNx0cmH0NtNRZs3NB5ubhpbX/bIt7l2zJOSyO64NGmwMAAACCeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXN5bmRpY2F0aW9uLmNvbTo0NDMiLCJmZWF0dXJlIjoiV2ViVmlld1hSZXF1ZXN0ZWRXaXRoRGVwcmVjYXRpb24iLCJleHBpcnkiOjE3MTk1MzI3OTksImlzU3ViZG9tYWluIjp0cnVlfQ=="><style type="text/css">.resize-observer[data-v-8859cc6c]{position:absolute;top:0;left:0;z-index:-1;width:100%;height:100%;border:none;background-color:transparent;pointer-events:none;display:block;overflow:hidden;opacity:0}.resize-observer[data-v-8859cc6c] object{display:block;position:absolute;top:0;left:0;height:100%;width:100%;overflow:hidden;pointer-events:none;z-index:-1}</style><style type="text/css">.vue-notification-group{display:block;position:fixed;z-index:5000}.vue-notification-wrapper{display:block;overflow:hidden;width:100%;margin:0;padding:0}.notification-title{font-weight:600}.vue-notification-template{background:#fff}.vue-notification,.vue-notification-template{display:block;box-sizing:border-box;text-align:left}.vue-notification{font-size:12px;padding:10px;margin:0 5px 5px;color:#fff;background:#44a4fc;border-left:5px solid #187fe7}.vue-notification.warn{background:#ffb648;border-left-color:#f48a06}.vue-notification.error{background:#e54d42;border-left-color:#b82e24}.vue-notification.success{background:#68cd86;border-left-color:#42a85f}.vn-fade-enter-active,.vn-fade-leave-active,.vn-fade-move{transition:all .5s}.vn-fade-enter,.vn-fade-leave-to{opacity:0}</style></head> <body class="font-sans h-100 leading-normal text-base text-indigo-50 bg-indigo-800" data-n-head="%7B%22class%22:%7B%22ssr%22:%22font-sans%20h-100%20leading-normal%20text-base%20text-indigo-50%20bg-indigo-800%22%7D%7D" aria-hidden="false"> <div data-server-rendered="true" id="__nuxt"><!----><div id="__layout"><div class="flex flex-col justify-between min-h-screen"><header role="banner" data-fetch-key="0" class="b-header h-14"><div class="b-header__navbar relative w-full h-14 z-50  py-3 flex flex-col justify-center transform transition-transform duration-150 ease-in-out  bg-indigo-500 shadow-3xl"><div class="px-4 sm:px-6 md:px-8 w-full max-w-[1444px] mx-auto !max-w-full"><div class="flex w-full md:gap-2 md:gap-2"><div class="flex flex-initial gap-4 md:gap-6 w-full xl:w-auto items-center justify-between"><div class="flex w-full gap-4 md:gap-6 items-center flex-1"><div class="relative z-50 flex-initial xl:flex-initial"><a href="/"><div class="inline-block"><img src="/images/logo.svg" width="137" height="24" alt="Strike.Market" class="hidden sm:inline-block"> <img src="/images/symbol.svg" width="32" height="32" alt="Strike.Market" class="inline-block sm:hidden"></div></a></div> <div class="flex-1 w-full max-w-md 2xl:max-w-2xl xl:w-80 2xl:w-128"><div class="b-ticker-search md:relative"><div class="relative"><div placeholder="Search for tickers..." value="" class="inline-block relative w-full"><input type="search" placeholder="Search for tickers..." value="" class="text-sm px-4 py-2.5 bg-indigo-800 border-indigo-900 placeholder-indigo-200 w-full b-input border rounded leading-tight tracking-wide font-normal text-indigo-50 shadow-inner outline-none placeholder-opacity-100 focus:ring-1 focus:ring-offset-1 focus:ring-offset-transparent focus:ring-indigo-400 focus:ring-opacity-50 appearance-none"> <!----></div> <span class="absolute top-1/2 transform -translate-y-1/2 right-2 text-indigo-300"><span class="p-2"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="search" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" class="svg-inline--fa fa-search fa-w-16"><path fill="currentColor" d="M505 442.7L405.3 343c-4.5-4.5-10.6-7-17-7H372c27.6-35.3 44-79.7 44-128C416 93.1 322.9 0 208 0S0 93.1 0 208s93.1 208 208 208c48.3 0 92.7-16.4 128-44v16.3c0 6.4 2.5 12.5 7 17l99.7 99.7c9.4 9.4 24.6 9.4 33.9 0l28.3-28.3c9.4-9.4 9.4-24.6.1-34zM208 336c-70.7 0-128-57.2-128-128 0-70.7 57.2-128 128-128 70.7 0 128 57.2 128 128 0 70.7-57.2 128-128 128z"></path></svg></span></span></div> <!----></div></div></div> <div class="flex-initial px-2 md:px-4 xl:hidden"><button type="button" aria-label="Show menu" class="relative block z-50 outline-none focus:outline-none active:outline-none w-12 py-3 -mx-4 text-indigo-100 flex flex-col justify-center items-center"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="bars" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" class="text-3xl  svg-inline--fa fa-bars fa-w-14"><path fill="currentColor" d="M16 132h416c8.837 0 16-7.163 16-16V76c0-8.837-7.163-16-16-16H16C7.163 60 0 67.163 0 76v40c0 8.837 7.163 16 16 16zm0 160h416c8.837 0 16-7.163 16-16v-40c0-8.837-7.163-16-16-16H16c-8.837 0-16 7.163-16 16v40c0 8.837 7.163 16 16 16zm0 160h416c8.837 0 16-7.163 16-16v-40c0-8.837-7.163-16-16-16H16c-8.837 0-16 7.163-16 16v40c0 8.837 7.163 16 16 16z"></path></svg></button></div></div> <div class="flex flex-1 justify-between b-header__menu"><div class="min-h-full flex flex-1 flex-col justify-between xl:hidden"><div class="flex flex-col divide-y divide-indigo-500"><!----> <div><div class="-mx-6"><div class="text-2xl text-white leading-tight font-extrabold"><a href="/screener" class="group flex justify-between hover:bg-indigo-700"><span class="block"><span class="inline-block px-4 py-4 relative"><span class="whitespace-nowrap"><span class="text-2xl pr-1.5">üöÄ</span>Stock screener</span></span></span></a></div></div> <div class="ml-3.5 -mr-5"><div class="py-1 px-5 mb-6 xl:mb-1"><ul class="text-lg leading-tight -my-2 xl:-my-1 -mx-5 xl:-mx-2"><li><a href="/screener/nasdaq-stock-screener" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 text-indigo-50 hover:text-white xl:hover:underline">
                          Nasdaq Stock Screener
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/screener/sp-500-stock-screener" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 text-indigo-50 hover:text-white xl:hover:underline">
                          S&amp;P 500 Stock Screener
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/screener/otc-stock-screener" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 text-indigo-50 hover:text-white xl:hover:underline">
                          OTC Stock Screener
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li></ul></div> <div class="py-1 px-5 mb-6 xl:mb-1"><ul class="text-lg leading-tight -my-2 xl:-my-1 -mx-5 xl:-mx-2"><li><a href="/screener/best-growth-stocks" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 text-indigo-50 hover:text-white xl:hover:underline">
                          Best Growth Stocks
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/screener/low-pe-stocks" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 text-indigo-50 hover:text-white xl:hover:underline">
                          Low P/E stocks
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/screener/founder-led-companies" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 text-indigo-50 hover:text-white xl:hover:underline">
                          Founder-led companies
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li></ul></div> <div class="py-1 px-5 mb-6 xl:mb-1"><ul class="text-lg leading-tight -my-2 xl:-my-1 -mx-5 xl:-mx-2"><li><a href="/screener/ev-stocks" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 text-indigo-50 hover:text-white xl:hover:underline">
                          EV Stocks
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/screener/airline-stocks" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 text-indigo-50 hover:text-white xl:hover:underline">
                          Airline Stocks
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/screener/blue-chip-stocks" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 text-indigo-50 hover:text-white xl:hover:underline">
                          Blue Chip Stocks
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li></ul></div></div></div> <div><div class="-mx-4"><div class="text-2xl text-white leading-tight font-extrabold"><span class="block"><span class="inline-block px-4 py-4 relative"><span class="whitespace-nowrap"><span class="text-2xl pr-1.5">üöÄ</span> Market</span></span></span></div></div> <div class="ml-3.5 -mr-5"><div class="py-1 px-5 mb-6 xl:mb-1"><div class="text-base uppercase text-indigo-200 font-bold mb-3 xl:mb-2">Discover</div> <ul class="text-lg leading-tight -my-2 xl:-my-1 -mx-5 xl:-mx-2"><li><a href="/stocks-with-high-potential-upside" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 text-indigo-50 hover:text-white xl:hover:underline">
                          Stocks with high potential upside
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/biggest-stock-gainers-today" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 text-indigo-50 hover:text-white xl:hover:underline">
                          Biggest stock gainers today
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/biggest-stock-losers-today" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 hover:text-white xl:hover:underline">
                          Biggest stock losers today
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li></ul></div> <div class="py-1 px-5 mb-6 xl:mb-1"><div class="text-base uppercase text-indigo-200 font-bold mb-3 xl:mb-2">Stock Market Today</div> <ul class="text-lg leading-tight -my-2 xl:-my-1 -mx-5 xl:-mx-2"><li><a href="/us-stock-market-holidays" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 hover:text-white xl:hover:underline">
                          U.S. Stock Market Holiday
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li></ul></div> <div class="py-1 px-5 mb-6 xl:mb-1"><div class="text-base uppercase text-indigo-200 font-bold mb-3 xl:mb-2">Calendars</div> <ul class="text-lg leading-tight -my-2 xl:-my-1 -mx-5 xl:-mx-2"><li><a href="/earnings-calendar" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 hover:text-white xl:hover:underline">
                          Earnings Calendar
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/earnings-calendar/sp-500" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 hover:text-white xl:hover:underline">
                          S&amp;P 500 Earnings Calendar
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/earnings-calendar/nasdaq" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 hover:text-white xl:hover:underline">
                          Nasdaq Earnings Calendar
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/earnings-calendar/dow-jones" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 hover:text-white xl:hover:underline">
                          Dow Jones Earnings Calendar
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/earnings-calendar/tech-stocks" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 hover:text-white xl:hover:underline">
                          Tech Earnings Calendar
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/earnings-calendar/banks-stocks" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 hover:text-white xl:hover:underline">
                          Banks Earnings Calendar
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li></ul></div> <div class="py-1 px-5 mb-6 xl:mb-1"><div class="text-base uppercase text-indigo-200 font-bold mb-3 xl:mb-2">Directories</div> <ul class="text-lg leading-tight -my-2 xl:-my-1 -mx-5 xl:-mx-2"><li><a href="/stocks" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 hover:text-white xl:hover:underline">
                          Stocks
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/key-executives" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 hover:text-white xl:hover:underline">
                          Key executives
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/analysts" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 hover:text-white xl:hover:underline">
                          Wall Street Analysts
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li></ul></div></div></div> <div><div class="-mx-6"><div class="text-2xl text-white leading-tight font-extrabold"><div class="group flex justify-between hover:bg-indigo-700"><span class="inline-flex items-center gap-2 px-6 py-4 relative"><span class="whitespace-nowrap"><span class="text-2xl pr-1.5">üéì</span> Academy</span> <span class="b-badge b-badge inline-block whitespace-nowrap text-white rounded-full shadow-sm bg-green-600 text-green-50 text-2xs px-2 py-1 font-bold leading-none">New</span></span></div></div></div> <div class="ml-3.5 -mr-5"><div class="py-1 px-5 mb-6 xl:mb-1"><ul class="text-lg leading-tight -my-2 xl:-my-1 -mx-5 xl:-mx-2"><li><a href="/academy/alternative-data" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 text-indigo-50 hover:text-white xl:hover:underline">
                          Alternative data
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li> <li><a href="/academy/interviews" class="group text-lg flex justify-between items-center xl:inline-block font-bold xl:font-medium hover:bg-indigo-700 xl:hover:bg-transparent py-2 xl:py-1 px-5 xl:px-2 text-indigo-50 hover:text-white xl:hover:underline">
                          Interviews
                          <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="angle-right" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 256 512" class="text-xl text-opacity-75 group-hover:text-opacity-100 transition svg-inline--fa fa-angle-right fa-w-8"><path fill="currentColor" d="M224.3 273l-136 136c-9.4 9.4-24.6 9.4-33.9 0l-22.6-22.6c-9.4-9.4-9.4-24.6 0-33.9l96.4-96.4-96.4-96.4c-9.4-9.4-9.4-24.6 0-33.9L54.3 103c9.4-9.4 24.6-9.4 33.9 0l136 136c9.5 9.4 9.5 24.6.1 34z"></path></svg></a></li></ul></div></div></div> <div><div class="-mx-6"><div class="text-2xl text-white leading-tight font-extrabold"><a href="/funds" class="group flex justify-between hover:bg-indigo-700"><span class="block"><span class="inline-flex items-center gap-2 px-6 py-4 relative"><span class="whitespace-nowrap"><span class="text-2xl pr-1.5">üè¶</span> Hedge funds</span> <span class="b-badge b-badge inline-block whitespace-nowrap text-white rounded-full shadow-sm bg-green-600 text-green-50 text-2xs px-2 py-1 font-bold leading-none">New</span></span></span></a></div></div></div></div> <div class="mt-4"><div class="grid grid-cols-2 gap-4"><a href="/signin" target="_self" class="from-blue-600 to-blue-800 text-blue-50 hover:text-white focus:ring-1 font-bold text-sm px-4 py-2.5 rounded btn relative border leading-tight inline-flex items-center justify-center text-left bg-gradient-to-br bg-150% bg-left-top hover:bg-right-bottom border-transparent shadow outline-none active:shadow2 select-none transition-all ease-in-out duration-100 focus:outline-none active:outline-none focus:ring-offset-1 focus:ring-offset-transparent focus:ring-indigo-400 focus:ring-opacity-50"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="sign-in-alt" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" class="mr-2 svg-inline--fa fa-sign-in-alt fa-w-16"><path fill="currentColor" d="M416 448h-84c-6.6 0-12-5.4-12-12v-40c0-6.6 5.4-12 12-12h84c17.7 0 32-14.3 32-32V160c0-17.7-14.3-32-32-32h-84c-6.6 0-12-5.4-12-12V76c0-6.6 5.4-12 12-12h84c53 0 96 43 96 96v192c0 53-43 96-96 96zm-47-201L201 79c-15-15-41-4.5-41 17v96H24c-13.3 0-24 10.7-24 24v96c0 13.3 10.7 24 24 24h136v96c0 21.5 26 32 41 17l168-168c9.3-9.4 9.3-24.6 0-34z"></path></svg> Sign in</a> <a href="/signup" target="_self" class="from-blue-600 to-blue-800 text-blue-50 hover:text-white focus:ring-1 font-bold text-sm px-4 py-2.5 rounded btn relative border leading-tight inline-flex items-center justify-center text-left bg-gradient-to-br bg-150% bg-left-top hover:bg-right-bottom border-transparent shadow outline-none active:shadow2 select-none transition-all ease-in-out duration-100 focus:outline-none active:outline-none focus:ring-offset-1 focus:ring-offset-transparent focus:ring-indigo-400 focus:ring-opacity-50"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="user-plus" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 640 512" class="mr-2 svg-inline--fa fa-user-plus fa-w-20"><path fill="currentColor" d="M624 208h-64v-64c0-8.8-7.2-16-16-16h-32c-8.8 0-16 7.2-16 16v64h-64c-8.8 0-16 7.2-16 16v32c0 8.8 7.2 16 16 16h64v64c0 8.8 7.2 16 16 16h32c8.8 0 16-7.2 16-16v-64h64c8.8 0 16-7.2 16-16v-32c0-8.8-7.2-16-16-16zm-400 48c70.7 0 128-57.3 128-128S294.7 0 224 0 96 57.3 96 128s57.3 128 128 128zm89.6 32h-16.7c-22.2 10.2-46.9 16-72.9 16s-50.6-5.8-72.9-16h-16.7C60.2 288 0 348.2 0 422.4V464c0 26.5 21.5 48 48 48h352c26.5 0 48-21.5 48-48v-41.6c0-74.2-60.2-134.4-134.4-134.4z"></path></svg> Sign up</a></div></div></div> <div class="hidden xl:flex flex-1 items-center justify-between text-center"><div class="lg:mr-4 flex flex-1 divide-x divide-indigo-400"><!----> <div><div class="outline-none text-left inline-block"><div class="inline-block"><a href="/screener" target="_self" id="__trigger" class="bg-transparent hover:text-yellow-300 hover:bg-indigo-900 hover:bg-opacity-25 shadow-none active:shadow-none border-transparent font-bold text-sm px-4 py-2.5 btn relative border leading-tight inline-flex items-center justify-center text-left bg-gradient-to-br bg-150% bg-left-top hover:bg-right-bottom border-transparent shadow outline-none active:shadow2 select-none transition-all ease-in-out duration-100 focus:outline-none active:outline-none focus:ring-offset-1 focus:ring-offset-transparent focus:ring-indigo-400 focus:ring-opacity-50 h-14"><!----> <!----> <span class="whitespace-nowrap"><span class="text-lg pr-1.5">üîé</span> Stock screener</span> <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="chevron-down" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" class="svg-inline--fa fa-chevron-down fa-w-14 ml-1.5 mt-0.5 transform transition-transform scale-75 ease-in-out duration-100 rotate-0"><path fill="currentColor" d="M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z"></path></svg></a></div> <!----></div></div> <div><div class="outline-none text-left inline-block"><div class="inline-block"><button type="button" id="__trigger" class="bg-transparent hover:text-yellow-300 hover:bg-indigo-900 hover:bg-opacity-25 shadow-none active:shadow-none border-transparent font-bold text-sm px-4 py-2.5 btn relative border leading-tight inline-flex items-center justify-center text-left bg-gradient-to-br bg-150% bg-left-top hover:bg-right-bottom border-transparent shadow outline-none active:shadow2 select-none transition-all ease-in-out duration-100 focus:outline-none active:outline-none focus:ring-offset-1 focus:ring-offset-transparent focus:ring-indigo-400 focus:ring-opacity-50 h-14"><!----> <!----> <span class="whitespace-nowrap"><span class="text-lg pr-1.5">üöÄ</span> Market</span> <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="chevron-down" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" class="svg-inline--fa fa-chevron-down fa-w-14 ml-1.5 mt-0.5 transform transition-transform scale-75 ease-in-out duration-100 rotate-0"><path fill="currentColor" d="M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z"></path></svg></button></div> <!----></div></div> <div><div disable="8" class="outline-none text-left inline-block"><div class="inline-block"><button type="button" id="__trigger" class="bg-transparent hover:text-yellow-300 hover:bg-indigo-900 hover:bg-opacity-25 shadow-none active:shadow-none border-transparent font-bold text-sm px-4 py-2.5 btn relative border leading-tight inline-flex items-center justify-center text-left bg-gradient-to-br bg-150% bg-left-top hover:bg-right-bottom border-transparent shadow outline-none active:shadow2 select-none transition-all ease-in-out duration-100 focus:outline-none active:outline-none focus:ring-offset-1 focus:ring-offset-transparent focus:ring-indigo-400 focus:ring-opacity-50 h-14"><!----> <!----> <span class="whitespace-nowrap"><span class="text-lg pr-1.5">üéì</span> Academy</span> <span class="b-badge absolute top-1 right-2 scale-90 b-badge inline-block whitespace-nowrap text-white rounded-full shadow-sm bg-green-600 text-green-50 text-4xs px-1 py-0.5 font-extrabold tracking-wide leading-tight">New</span> <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="chevron-down" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" class="svg-inline--fa fa-chevron-down fa-w-14 ml-1.5 mt-0.5 transform transition-transform scale-75 ease-in-out duration-100 rotate-0"><path fill="currentColor" d="M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z"></path></svg></button></div> <!----></div></div> <div><a href="/funds" target="_self" class="h-14 bg-transparent hover:text-yellow-300 hover:bg-indigo-900 hover:bg-opacity-25 shadow-none active:shadow-none border-transparent font-bold text-sm px-4 py-2.5 w-full text-center btn relative border leading-tight inline-flex items-center justify-center text-left bg-gradient-to-br bg-150% bg-left-top hover:bg-right-bottom border-transparent shadow outline-none active:shadow2 select-none transition-all ease-in-out duration-100 focus:outline-none active:outline-none focus:ring-offset-1 focus:ring-offset-transparent focus:ring-indigo-400 focus:ring-opacity-50"><span class="whitespace-nowrap"><span class="text-base pr-1.5">üè¶</span> Hedge funds</span> <span class="b-badge hidden2 absolute top-1 right-2 scale-90 b-badge inline-block whitespace-nowrap text-white rounded-full shadow-sm bg-green-600 text-green-50 text-4xs px-1 py-0.5 font-extrabold tracking-wide leading-tight">New</span></a></div></div> <div class="flex md:gap-2 flex-initial"><div class="p-4 lg:p-0 text-center"><div class="outline-none text-left relative inline-block"><div class="inline-block"><button type="button" id="__trigger" class="bg-transparent hover:text-yellow-300 hover:bg-indigo-900 hover:bg-opacity-25 shadow-none active:shadow-none border-transparent font-bold text-sm px-4 py-2.5 rounded btn relative border leading-tight inline-flex items-center justify-center text-left bg-gradient-to-br bg-150% bg-left-top hover:bg-right-bottom border-transparent shadow outline-none active:shadow2 select-none transition-all ease-in-out duration-100 focus:outline-none active:outline-none focus:ring-offset-1 focus:ring-offset-transparent focus:ring-indigo-400 focus:ring-opacity-50"><!----> <span>Sign in</span>  <svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="chevron-down" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" class="svg-inline--fa fa-chevron-down fa-w-14 ml-1.5 mt-0.5 transform transition-transform scale-75 ease-in-out duration-100 rotate-0"><path fill="currentColor" d="M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z"></path></svg></button></div> <!----></div></div> <div class="p-4 lg:p-0 text-center"><a href="/signup" target="_self" class="from-blue-600 to-blue-800 text-blue-50 hover:text-white focus:ring-1 font-bold text-sm px-4 py-2.5 rounded btn relative border leading-tight inline-flex items-center justify-center text-left bg-gradient-to-br bg-150% bg-left-top hover:bg-right-bottom border-transparent shadow outline-none active:shadow2 select-none transition-all ease-in-out duration-100 focus:outline-none active:outline-none focus:ring-offset-1 focus:ring-offset-transparent focus:ring-indigo-400 focus:ring-opacity-50"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="user-plus" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 640 512" class="mr-2 svg-inline--fa fa-user-plus fa-w-20"><path fill="currentColor" d="M624 208h-64v-64c0-8.8-7.2-16-16-16h-32c-8.8 0-16 7.2-16 16v64h-64c-8.8 0-16 7.2-16 16v32c0 8.8 7.2 16 16 16h64v64c0 8.8 7.2 16 16 16h32c8.8 0 16-7.2 16-16v-64h64c8.8 0 16-7.2 16-16v-32c0-8.8-7.2-16-16-16zm-400 48c70.7 0 128-57.3 128-128S294.7 0 224 0 96 57.3 96 128s57.3 128 128 128zm89.6 32h-16.7c-22.2 10.2-46.9 16-72.9 16s-50.6-5.8-72.9-16h-16.7C60.2 288 0 348.2 0 422.4V464c0 26.5 21.5 48 48 48h352c26.5 0 48-21.5 48-48v-41.6c0-74.2-60.2-134.4-134.4-134.4z"></path></svg> Sign up</a></div></div></div></div></div></div></div></header> <main id="content" role="main" class="flex-auto overflow-x-auto-2 overflow-y-hidden-2"><div class="vue-notification-group" style="width:300px;top:0px;right:0px;"><span></span></div> <section class="bg-indigo-700 b-section relative py-8 md:py-10 xl:py-12"><!----> <div class="px-4 sm:px-6 md:px-8 w-full max-w-[1444px] mx-auto"><div class="hidden md:block"><nav aria-label="breadcrumb" class="b-breadcrumb text-xs md:text-sm leading-tight"><ol itemscope="itemscope" itemtype="http://schema.org/BreadcrumbList" class="flex -mx-2"><li itemprop="itemListElement" itemscope="itemscope" itemtype="http://schema.org/ListItem" class="relative"><a href="/" rel="home" itemscope="itemscope" itemtype="https://schema.org/WebPage" itemprop="item" itemid="/" class="px-2 text-indigo-200 hover:text-indigo-100 nuxt-link-active"><span itemprop="name">Home</span></a> <meta itemprop="position" content="1"></li><li itemprop="itemListElement" itemscope="itemscope" itemtype="http://schema.org/ListItem" class="relative"><a href="/stocks" itemscope="itemscope" itemtype="https://schema.org/WebPage" itemprop="item" itemid="/stocks" class="px-2 text-indigo-200 hover:text-indigo-100 nuxt-link-active"><span itemprop="name">Stocks</span></a> <meta itemprop="position" content="2"></li><li itemprop="itemListElement" itemscope="itemscope" itemtype="http://schema.org/ListItem" class="relative"><a href="/stocks/RDUS" itemscope="itemscope" itemtype="https://schema.org/WebPage" itemprop="item" itemid="/stocks/RDUS" class="px-2 text-indigo-200 hover:text-indigo-100 nuxt-link-active"><span itemprop="name">RDUS</span></a> <meta itemprop="position" content="3"></li><li itemprop="itemListElement" itemscope="itemscope" itemtype="http://schema.org/ListItem" class="relative"><a href="/stocks/RDUS/earnings-call-transcripts" itemscope="itemscope" itemtype="https://schema.org/WebPage" itemprop="item" itemid="/stocks/RDUS/earnings-call-transcripts" class="px-2 text-indigo-200 hover:text-indigo-100 nuxt-link-active"><span itemprop="name">Earnings Call Transcripts</span></a> <meta itemprop="position" content="4"></li><li itemprop="itemListElement" itemscope="itemscope" itemtype="http://schema.org/ListItem" class="relative"><span itemscope="itemscope" itemtype="https://schema.org/WebPage" itemprop="item" class="px-2 text-indigo-200"><span itemprop="name">Q4 2017</span></span> <meta itemprop="position" content="5"></li></ol></nav></div> <div class="text-center mt-4"><h1 class="text-4xl md:text-5xl font-extrabold leading-heading text-white">Radius Health, Inc.<br> <strong class="text-yellow-400">Q4 2017 Earnings Call Transcript</strong></h1> <p class="text-indigo-200 text-sm uppercase mt-2 mb-1">Published: <time>2 Mar 2018</time></p></div></div></section> <div aria-hidden="true" class="text-indigo-700"><svg fill="none" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 1440 64"><path opacity=".3" d="M0 0v25c57 12 124 17 190 15 84-3 163-18 248-20 88-3 177 9 262 18 83 10 166 14 251 7 43-3 84-9 125-15 111-17 260-38 364-2V0H0z" fill="#currentColor"></path> <path opacity=".5" d="M0 0v8c16 12 33 22 57 30 62 21 141 21 212 11 38-6 73-14 108-21C426 17 479 3 534 1c44-1 85 5 118 17 39 13 75 33 125 39 48 6 97-4 143-13 45-9 90-21 140-23 72-3 136 12 203 21a306 306 0 00177-31V0H0z" fill="currentColor"></path> <path d="M0 0v3c180 28 377 35 571 20 52-4 101-11 153-14 71-5 135 6 199 18 71 14 140 24 218 21 104-4 207-24 299-45V0H0z" fill="currentColor"></path></svg></div> <section class="b-section relative py-8 md:py-10 xl:py-12"><!----> <div class="px-4 sm:px-6 md:px-8 w-full max-w-[1444px] mx-auto -mt-16 md:-mt-24 xl:-mt-32"><div class="relative mx-auto max-w-screen-sm xl:max-w-screen-md 2xl:max-w-screen-lg"><div aria-hidden="true" class="hidden lg:block relative"><div class="absolute top-0 right-full mr-6 xl:mr-8 pointer-events-auto"><ins data-ad-client="ca-pub-9608158334186947" data-ad-slot="8791087257" data-ad-format="auto" data-adtest="off" data-full-width-responsive="true" class="adsbygoogle" style="display:inline-block;width:160px;height:600px;"></ins></div> <div class="absolute top-0 left-full ml-6 xl:ml-8 pointer-events-auto"><ins data-ad-client="ca-pub-9608158334186947" data-ad-slot="8791087257" data-ad-format="auto" data-adtest="off" data-full-width-responsive="true" class="adsbygoogle" style="display:inline-block;width:160px;height:600px;"></ins></div></div> <div class="b-content content leading-relaxed mx-auto mb-6 max-w-screen-lg"><ins data-ad-client="ca-pub-9608158334186947" data-ad-slot="4468698860" data-ad-format="auto" data-adtest="off" data-full-width-responsive="true" class="adsbygoogle" style="display:block;"></ins></div> <div class="relative card flex-col justify-between bg-indigo-600 rounded shadow-lg flex"><!----> <div class="p-4 md:p-6"><div class="b-content content leading-relaxed text-indigo-100"><ul class="b-list b-list--card -mx-4 md:-mx-6"><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-indigo-200" style="flex-basis:0px;">Operator:</dt> <dd class="flex-auto">Good day, ladies and gentlemen and welcome to the Radius Health fourth quarter and full year 2017 earnings conference call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to Elhan Webb, Head of Investor Relations. Ma‚Äôam, you may begin.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Elhan Webb:</dt> <dd class="flex-auto">Thank you, Shannon. Good evening, and thank you all for joining us on the conference call and webcast for Radius's fourth quarter and full year 2017 financial results and business update. Joining me today are Jesper H√∏iland, President and Chief Executive Officer; Joe Kelly, our Senior VP of Sales and Marketing; Gary Hattersley, our Chief Scientific Officer; and Pepe Carmona, our Chief Financial Officer. Before we begin, I would like to remind you that statements made during this call that are not historical facts are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the Risk Factors section in our annual report on Form 10-K for the period ended December 31, 2017 and other reports filed with the Securities and Exchange Commission. Any forward-looking statements represent our views as of today, March 1, 2018, only. A replay of this call will be available on the company's website, www.radiuspharm.com. And you can find the dial-in information for the conference call replay in today's press release as well as on the company's website. Today‚Äôs agenda is intended to provide you with a review of what we accomplished in 2017, and update on the TYMLOS launch, our fourth quarter and full year 2017 financials, and update on our development plans for our abaloparatide patch, elacestrant and upcoming corporate milestones. At the end of the call, the management team will be available to answer questions. I'd like to now turn the call over to Jesper H√∏iland, Radius's President and Chief Executive Officer. Jesper?</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Jesper H√∏iland:</dt> <dd class="flex-auto">Thank you, Elhan. Welcome everybody and thank you for joining us today. As many of you may already know, we brought on Elhan Webb as our new Head of Investor Relationships and External Communications at the beginning of this year. She comes to us with a considerable global experience, working with both the sell side and buy side analysts as well as her experience as an investment portfolio manager. We are very happy to have Elhan on board. On slide number 5, you will see that Radius achieved a lot in the year of 2017. It has been a transformational year for Radius Health, becoming a fully integrated commercial biopharmaceutical company, committed to bone health and oncology through innovative therapies. A few of our most significant achievements were the FDA approval and subsequent the US commercialization of abaloparatide subcutaneously, named TYMLOS, a bone building agent for the treatment of post-menopausal women with osteoporosis at high risk of fracture. The initiation of our Phase 1 clinical trial for RAD140, a serum for the potential treatment of hormone receptor positive breast cancer and the FDA fast track designation granted for elacestrant, an all investigational search for the treatment of women in metastatic breast cancer. Further, we ended the year with 430 million in cash and the balance sheet strength to support our future growth and plans. We have also built a strong commercial organization to establish TYMLOS leadership. Finally, our successes will not have been possible without the passion and dedication of our talented employees and of course the strong support of our investors, and I want to take this opportunity to thank all of you for your commitment and support. With our new management team in place, we will continue to build on the momentum with several key initiatives underway to accelerate the advancement of our pipeline, establish a strong foundation to maximize our commercial potential, and to continue to build shareholder value. Slide number 6. As you can see, we are well on the way to successfully penetrating the osteoporosis anabolic segment to become the number one leader in the market. Our intention here is to expand further geographically by partnering outside of the US, while we focus our commercial efforts in the US market. We are actively working on expanding and differentiating the TYMLOS label so that we can reach a leadership position in the osteoporosis market. We expect the TYMLOS patch to disrupt and significantly expand the anabolic osteoporosis market as well. Today, we're announcing our path forward for the development of the abaloparatide-patch after the alignment meeting with FDA and our strategic partnership with 3M Company. Gary and I will discuss this more in detail later on in the presentation. In oncology, Radius continued to gain a foothold in breast cancer through Elacestrant, a potential backbone hormonal therapy. Our focus is to initiate a study in third-line therapy and engage in collaboration agreements for the developed and earlier lines of therapy. We will be focused on the commercialization in the US, while partnering outside of the US. Additionally, we will continue to fuel our breast cancer pipeline with RAD140. Today, we are also announcing that based on the feedback from FDA and EMEA, we have decided to initiate the comparator Phase 2 trial potentially a pivotal study to support global registration. We believe, Elacestrant is the leading SERD in the development and has the potential to maximize its value through the global clinical and regulatory pathway. And here on slide number 7, you‚Äôre going to see that we recently announced our commercial leadership changes with the appointment of Joe Kelly as Senior Vice President of Sales and Marketing, and the promotion of Amanda Mott to Senior Vice President of Market Access. Those two will drive the execution of our sales and marketing strategy to best position TYMLOS as the market leader. Joe has over 20 years of experience in sales and marketing in the US, a proven track record in growing billion dollar businesses and successfully launched several products that achieved market leadership. With more than 25 years of an industry experience in the US, Amanda has demonstrated a tremendous knowledge of the payer landscape, and expertise in setting and executing on our market access strategy. She has managed several portfolios in leading pharmaceutical companies and achieved number one market access positions in the US. We hope we will have the opportunity to introduce both of them personally to you in the near future. I will now turn over the call to Joe Kelly to give you a commercial update. Joe?</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Joe Kelly:</dt> <dd class="flex-auto">Thank you, Jesper. And I‚Äôm pleased to provide the full year 2017 TYMLOS performance update, covering the brand in its ninth month of market availability. Our commercial teams remain focused on achieving anabolic market leadership, and throughout the launch process, we kept a strong focus on key opinion leaders and top prescribers in the osteoporosis space where we have gained most of our market share to date. On slide 9, the response to TYMLOS from physicians, payers, and patients has been very positive. Since launching TYMLOS in May of 2017, we've been collecting feedback from anabolic prescribers to gauge their perceptions of the product as compared to other treatment options. As part of our customer surveys, which tracks awareness, trial and usage of TYMLOS amongst targeted physicians, we've learned that current prescribers highlight key attributes of the product, which they perceive as being meaningful and differentiated from other available therapies. These include rapid onset of action and convenience for patients due to carry and storage. On the next slide, I'm also pleased to share that we continue to see growth and manage market access across all segments as coverage increased to 259 million total covered lives. Since the launch of TYMLOS, we see a shifting of the anabolic patient mix towards commercial where TYMLOS coverage in nine months exceeds Forteo‚Äôs after 15 years on the market. For Medicare Part D, products approved after the second quarter are not part of the standard Part D bidding process and require off cycle reviews. We are pleased to report that TYMLOS is already covered for 41% of lives through these off cycle reviews due to its clinical profile combined with savings for patients and this includes coverage on UnitedHealthcare, the nation's largest Medicare Part D insurance plan. We are actively working with our managed care customers on Part D coverage in both off cycle reviews and the 2019 standard bidding process. We look forward to sharing more wins once contracts are finalized. On slide 11, in addition to the exclusive win at ESI that went into effect January 1, TYMLOS is now the preferred anabolic agent on Aetna, Prime and Healthcare Services Corporation also known as HCSC, each having TYMLOS listed as their preferred anabolic for new patients also as of January 1 of this year. Because of these decisions, TYMLOS is now preferred for approximately 30% of the total anabolic volume in commercial. Performance wise, we are capturing patients with the ESI book a business in alignment with expectations and seen growth in the non-ESI and Medicare Part D plans. For 2018, we‚Äôll continue to be focused on market share growth across all segments of business. On the next slide, our top TYMLOS prescribers are coming from our most important customers in the top 200 and tier 1 segments, which make up about 7000 providers. With our strong focus on consistently calling on the highest potential health care providers in osteoporosis, results have been that 88% of TYMLOS business to date is coming from this important tier. We've also built out our promotional speakers‚Äô bureau from 50 key opinion leaders to over 70 who have local, regional and national influence within the osteoporosis space. Slide 13 shows that prior to the second quarter of 2017, the anabolic class has been in decline for five years. What we see now is quarterly volume growth from 3% to 6% over the last three individual quarters. With our efforts across the commercial team and promoting TYMLOS, we are playing a significant part in the growth of the anabolic segment. Also important is when we look across the TYMLOS prescribers, we've found new or returning writers account for 12% of total TYMLOS volume today. Since we are in the early stages of launch, it's too soon to project market and new prescriber growth, but we do see this as encouraging signs of market potential. On slide 14, we're also seeing an acceleration in our ability to acquire new patients as reflected by our NBRx trend, which has more than doubled since the beginning of November of last year. With NBRx being a lead indicator, we expect to see continued anabolic share growth as we improve coverage and get more time with healthcare providers who are active in treating their patients with osteoporosis. In summary, our number one priority is to continue executing the launch of TYMLOS in the US and to establish Radius as the market leader in the anabolic osteoporosis space. We will continue our focus on strong execution by the commercial team and drive TYMLOS market share growth where we have formulary coverage with key commercial and Part D payers. We believe successful in these efforts will drive sustainable growth for the organization, which in turn is beneficial for shareholders and of course the patients we serve. So, thank you. Now, I would like to turn over the call to Pepe Carmona to go over the fourth quarter and 2017 financials.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Pepe Carmona:</dt> <dd class="flex-auto">Thank you, Joe. This is our second quarter full quarter reporting TYMLOS sales. The three months ended December 31, 2017, Radius reported net sales of $7.7 million dollars and a loss of $71 million or $1.59 per share as compared to a net loss of $53 million or $1.22 per share for the three months ended December 31, 2016. The $7.7 million sales figure represents three months of shipments discounted by gross to net adjustments. Our revenue recognition policy is in line with US GAAP and it is described in our Form 10-K On the right side of the slide, we show the figures on non-US GAAP basis, which excludes share-based compensation, intangible asset amortization and non-cash interest from the convertible note. You can see the reconciliation between GAAP and non-GAAP in the appendix. Radius on a non-US GAAP basis for the same period reported a net loss of $61 million or $1.38 per share as compared to a net loss of $45 million or $1.05 per share for the three months ended December 31, 2016. I would like to highlight three points. First, our gross margin was reported at 92%, which includes 5% of royalties. Second, the slight decline in R&amp;D expenses versus Q4 of 2016 is driven by the reduction of the abaloparatide SC study expenses. Last, the SG&amp;A increase is driven by the ramp up in support of TYMLOS commercialization and some back office support functions. We're now a fully staffed commercial company with over 200 sales reps working in the field and approximately 20 MSAs, all working to support TYMLOS. As we have said to you before, we‚Äôre allocating resources in accordance with our strategy, which is to drive TYMLOS growth and continue advancing our pipeline. Turning to slide 17, we show our cash, cash equivalents and marketable securities balance as of December 31, 2017, which was $430 million. In the fourth quarter, we reduced our cash balance by $38 million. Most of the uses of cash was for the TYMLOS commercialization and R&amp;D external expenses related to the ramp-up of the products in our pipeline. We have cash inflows from TYMLOS revenues and from the Teijin deal, from which we recognized the license revenues in Q3 2017, but the actual cash was collected this quarter. Finally, I would like to leave you with a thought that at the end of 2017, Radius is in a strong financial position. We have sufficient capital to fund our key development plans, US commercial and other operational activities. Moving to slide 18, let me quickly show you how we transformed the company throughout the quarters in 2017. You can see that in Q1, we hired most of the commercial organization, which had a full quarter impact into Q2. Then in Q2 of 2017, we launched TYMLOS and started to invest in promotional material, which was fully ramped up by Q3. Then in Q3 of 2017, we started buying material and pay our CRO to prepare the elacestrant phase 2 study. And finally, in Q4, we initiated investments to prepare the male OP study and had some one-off legal IP and swing item costs. We have a fully staffed organization, so you can see that our personnel costs are relatively stable in the last two quarters of the year. I look forward to your questions at the end of the call. With that, I will pass the call to Gary for the update on the clinical pipeline.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Gary Hattersley:</dt> <dd class="flex-auto">Thank you, Pepe. As shown on slide 20, we are continuing to support both lifecycle management for TYMLOS and our oncology programs for elacestrant and RAD140. For TYMLOS, as we've previously guided, we continue to expect a CHMP opinion on our MAA submission in the first half of 2018. We are initiating a male osteoporosis bridging study in the first quarter of 2018, which will be a randomized double-blind placebo-controlled study that would enroll approximately 225 men with osteoporosis. The primary endpoint will be change in lumbar spine BMD at 12 months and pending positive outcome from this study, this data would be the basis for a supplemental NDA submission to seek an expanded TYMLOS label. We are also initiating a short term [indiscernible] clinical study in the first half of 2018 and believe this study will provide important information to enhance our understanding of the early anabolic effects of TYMLOS and the relative contribution of bone remodeling and modeling to its anabolic bone building activity. And today, we will provide a significant update on the development of the abaloparatide patch, following alignment with the FDA and completion of a collaboration and supply agreement with 3M. But first some updates on the clinical development plan for elacestrant. At the recent San Antonio Breast Cancer Symposium in December, we provided a significant update on our ongoing Phase 1 study with elacestrant. In this study, which enrolled a heavily pretreated patient population, we reported a 27% ORR, a 47% CBR and a 5.4 month PFS. Importantly, responses we‚Äôre seeing patients to the previously received fulvestrant, CDK4/6 inhibitors and in patients with ESR1 mutations. Elacestrant was generally well tolerated with the most common adverse events of low grade nausea, dyspepsia and vomiting. We believe this data continues to be strongly supportive of the advancement of elacestrant to potentially pivotal phase 2 study. Before providing details of this study, it‚Äôs important to provide some further context for our data as shown on slide 22. When we look at response rates to hormonal agents in the late line setting, for example with Fulvestrant in the BELLE-3 study, which represents a third line patient population, it was a 2.1% response rate and even in a second line population, in studies like PALOMA-3 and SOFEA, the response rate was less than 10%. Similarly, for PFS, as shown on slide 23, Fulvestrant in the third line setting achieved a 1.8 months PFS and in the second line population, the PFS was less than five months. So based on our five Phase 1 updates at San Antonio in December, we remain very encouraged by the potential for elacestrant. As is typical in clinical development programs, we have recently had further engagement with the FDA around potential pathways to registration and while a single arm study together with a confirmatory study remains an option, our strategy has been to have a pathway that supports both global approval. So we instead intend to conduct a randomized comparator controlled study. This is a well-established part that could support registration for elacestrant as a third line monotherapy. We‚Äôve also engaged the EMA and received feedback for the comparator study may also support EU registration. This study would enroll approximately 300 patients with estrogen-receptor-positive, HER2 negative advanced for metastatic breast cancer that will be randomized to receive either elacestrant or investigator‚Äôs choice to form with PFS as the primary endpoint. We will provide more details on the Phase 2 study when it's initiated, which we expect to occur in the second half of 2018. Based on the emerging clinical and preclinical profile for elacestrant, we see significant opportunities not only in the third line setting, but also in earlier lines of therapy, either as a monotherapy or in combination with other targeted use, a path we intend to pursue through strategic collaboration agreements. At this point, I'd like to switch focus and provide an update on the abaloparatide-patch. We're pleased to report significant progress with our short wear time patch program, which is a key component to extended TYMLOS franchise, which could provide an alternative to self-injection and the potential to enhance patient convenience. Our strategy is to bridge the patch to our proved TYMLOS products based on the BMD study. This is an established pathway to registration in osteoporosis and one that provides important pharmacodynamics, long-term safety and patient experience data for the patch. It's also worth noting that the time line to NDA submission is similar for either a BMD or PK bioequivalent strategy. We've aligned with the FDA on the pathway to support bridging and we have also completed a collaboration to supply agreement with 3M and Jesper will provide more details on this agreement later during this call. So in January, we met with the FDA to discuss the development pathway for the patch. Those agreements on a single, pivotal BMD non-inferiority study, which will be a two arm study with one to one randomization of patients to receive either abaloparatide subcu or the patch and the primary endpoint would be change in lumbar spine BMD at 12 months. Importantly, we have aligned on study power, sample size, and non-inferiority margin as well as on the supportive clinical and non-clinical studies required for NDA submission. We expect this pivotal study to initiate in mid-2019. The non-inferiority margin is based on preserving 75% of the treatment effect of the active comparator based on the lower bound of the 95% confidence interval. So using our Phase 3 active dataset as an example, where the mean change in lumbar spine BMD at 12 months was 9% with a lower bound of 8.5% to preserve 75% of the subcu treatment effect, the BMD 95% confidence interval with a patch would need to be greater than 6.4% to achieve non-inferiority. Our recent focus has been on the continued optimization of the patch to achieve comparability to subcu. As previously reported, our first prototype patch established the suitability and tolerability of this patch technology with over 36,000 individual patch applications made to over 250 patients, but due to the highly positive pharmacokinetic profile of this patch, BMD efficacy was suboptimal compared to subcu. Our second prototype patch introduced formulation technology, which was able to significantly enhance the pharmacokinetic profile with delayed Tmax, extended half-life and increased exposure. We have now completed optimization of the patch, which has been achieved through finalization of the formulation, process optimization, selection of dose and introduction of a new applicator. As shown on slide 31, this optimized patch achieves the target profile by further increasing half-life and exposure relative to earlier prototype patches. And importantly, as shown in the summary of clinical data in the table now achieves the same exposure as subcu. To evaluate the potential for this optimized patch to achieve BMD non-inferiority, we work with a third-party PKPD modeling and simulation company to develop an exposure response relationship model using our extensive Phase 3 active BMD and PK dataset. This approach established a clear relationship between BMD and exposure. So together with our optimized patch data, this allows an estimation of BMD gains and thereby enables an estimation of the probability to achieve non-inferiority. Slide 33 shows the time course of predicted BMD gains at the lumbar spine for subcu in orange and for the optimized patch in green, with both mean and 95% confidence interval values shown. Also shown on the figure is the BMD non-inferiority bar at the 12-month time point. We believe this analysis predicts a high probability of success for the patch to achieve non-inferiority in a 12-month BMD study. At this point, we are continuing to focus on commercial manufacturing scale-up activities for both the patch and the applicator together with the supportive clinical and non-clinical activities in preparation for the pivotal study and NDA. CMC preparation and manufacturing of clinical supplies are now key activities to support the initiation of the pivotal Phase 3 study, which we expect to occur in mid-2019 with study completion in 2020. At this point, I'd like to pass the call over to Jesper to provide comments on the patch opportunity and the collaboration agreements.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Jesper H√∏iland:</dt> <dd class="flex-auto">Thank you, Gary. I'm sure you can appreciate the excitement we at Radius for the development of the patch. We believe it has the potential to disrupt and grow the anabolic market. On slide 35, we like to share with you some of the qualitative research we have performed with patients, physicians and payers. We have received consistent responses that needle avoidance is a significant issue. This limits initiation and continuation of the anabolic therapy. There's a strong preference for pets versus an injection. Patients don't just fear injections per se, they fear by the injections represented, which is a serious illness. Patients would be much more willing to use a non-injectable and anabolic treatment because they feel less sickness and they are willing to confront their condition rather than deny severity. Some physicians notably DCPs who don't currently prescribe injectable anabolics indicated their willingness to prescribe a patch rather than referring the patients to specialists. They felt by providing the option of a patch versus an injection, they would be able to convince many of the high risk osteoporosis patients to start and stay on anabolic therapy and receive bone building benefits. And on slide 36, you can see why we believe the abaloparatide patch, if approved, can change the treatment paradigm and expand the anabolic market significantly. We see a large opportunity to expand the treatment for osteoporosis patients with anabolic therapy, not only to the patients with prior fracture, but also to patients who are at high risk of fracture, all have failed, all become intolerant to other available osteoporosis therapies. For physicians, our analysis reveals that the current -- only 17,000 physicians prescribing anabolics with the majority being specialists. With the introduction of the patch, we will be able to capture high volume osteoporosis prescribers and substantially expand our prescriber base. As you can see on the right side of the slide, anabolics is not the major expenses for the payers. Based on feedback from payers, the patch would be a valuable as it has the potential to improve patient compliance, outcomes and defray practice costs. Patch provides an opportunity to bring innovation and to be appropriately valued in the market. The osteoporosis market is valued at almost $3 billion. We are currently very excited to announce that we have recently entered into the worldwide partnership agreement with 3M for the exclusive manufacturing and supply of the abaloparatide patches and the key terms for the agreement are shown here on slide 37. In collaboration, we will cover certain capital expenditures ensured by 3M to set up the commercial manufacturing facility. After launch, 3M will supply us with coated patches at cost plus basis in a tiered pricing structure and will be entitled to a mid to low single digit royalty on worldwide net sales of the abaloparatide patch. So, to conclude, we are extremely excited to be moving forward with the development of our abaloparatide patch, having achieved an alignment with the regulatory path with FDA and collaboration agreement with 3M, the applied science leading innovator. The abaloparatide patch, if approved, has the potential to provide benefits of bone building therapy to many more osteoporosis patients. We see the patch as an important value driver for Radius, expanding the anabolic market and extending the abaloparatide franchise potentially up to 2037. As you can see on slide 40, we anticipate many inflection points that will significantly impact Radius going forward. So we expect 2018 to be very exciting for Radius with TYMLOS progressing towards market leadership and further advancing our pipeline. I would like to thank you all for your interest and support in Radius Health and I will like to ask that we open for calls now.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-indigo-200" style="flex-basis:0px;">Operator:</dt> <dd class="flex-auto">[Operator Instructions] Our first question comes from Jessica Fye with JP Morgan.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Jessica Fye:</dt> <dd class="flex-auto">I wanted to ask a couple about the elacestrant study. Specifically, can you help us think about what you expect the mix of dealers' choice and the current therapies to be in that trial? And then your patients have seen Aromatase inhibitor early on, potentially a third and the second line, what do you expect them to be randomized to in the control arm of your study? And then in addition, I think you mentioned an interim look in that one. Can you talk about when you project that might occur from a timing standpoint or what number of patients or progression of events would be triggered -- would trigger that interim?</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Jesper H√∏iland:</dt> <dd class="flex-auto">Thank you, Jessica. I will have Gary to answer.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Gary Hattersley:</dt> <dd class="flex-auto">At this point, we're not providing guidance on the details of the study. That‚Äôs just something that we will do once the study is initiated in the second half of this year. But certainly when we look at the types of hormonal agents that are used in a late line setting, there are relatively small number of options; and of course, as I think we try to highlight with some of the data here and at San Antonio, when we look at the response rates and the PFS for those hormonal agents in a late line setting, I think we have a very good handle on how they perform and I think it makes us very encouraged that elacestrant really has the potential to perform very well against the comparator, but again we‚Äôll provide more details when the study is initiated. We have guided that we are intending to perform an interim analysis. At this point, we're not providing any further detail around when that patent information may be available.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Jessica Fye:</dt> <dd class="flex-auto">And maybe just following up on that, is there a call in your Phase 1, patients had seen a number of prior therapies, including multiple different endocrine therapies, but should we expect the idea that these patients may have already seen multiple endocrine therapies to pose any enrollment challenges if an investigator might say, I‚Äôd love for you to try 1901 , but not sure you should be trying another product that you might have already failed on for example.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Gary Hattersley:</dt> <dd class="flex-auto">That's a very good question. We know in this late line setting, as you described, many of these patients will have progressed through several hormonal therapies earlier in treatments. It's not uncommon for hormonal agents to be reintroduced in a late line. Obviously, these patients have relatively few treatment options on certainly I think when we think about how elacestrant could perform in this late line setting or how we've seen it perform in our ongoing phase 1 study, again against patients that have previously received these endocrine agents, I think we feel very encouraged by Elacestrant‚Äôs potential.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Jessica Fye:</dt> <dd class="flex-auto">And maybe just last one on the patch study. Can you talk about your assumptions for enrolment? I just want to make sure I understand, as you're starting the study in mid-19 and expect to see data on a 12-month endpoint in 2020. Is it fair to imply you expect to get 500 patients enrolled in six months?</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Gary Hattersley:</dt> <dd class="flex-auto">Obviously, we're not providing specific guidance around enrolment. Certainly, Radius has a long history of conducting many BMD studies through the course of development for abaloparatide. So, I think we have a very good handle on what it would take to enroll these patients, how many sites that we would expect to be able to enroll these patients quickly. We certainly think with the study design in which patients are going to receive either the subcutaneous injection or the abaloparatide patch that this could be quite a -- study of patients may be enthusiastic about taking part in.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Jessica Fye:</dt> <dd class="flex-auto">Forgive me, but just one more on the patch, can you just talk a little bit more about how you got comfortable or convinced that the BMD effect is really AUC driven and not affected by the shape of the curve, now that it looks like you're very close on AUC but have moved away on Cmax and Tmax.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Gary Hattersley:</dt> <dd class="flex-auto">Yeah. So the Cmax and the Tmax is the same -- within the target for subcutaneous injection, but it's really heavily driven by our experience with our active Phase 3 dataset. That is a very rich dataset in which we have several thousand PK data points as well as we have BMD values from a large number of patients across multiple time points. That's really been a data set that‚Äôs allowed us to construct this exposure response model to be able to look at multiple PK parameters, and I think our analysis, where we input the transdermal patch data into that model gives us a very high degree of confidence that the patch we have right now is optimized patch, has the profile that it needs to be able to achieve the BMD endpoints and to be successful in a non-inferiority BMD study.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-indigo-200" style="flex-basis:0px;">Operator:</dt> <dd class="flex-auto">Our next question comes from Matthew Harrison with Morgan Stanley.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Matthew Harrison:</dt> <dd class="flex-auto">I think maybe two from me. So first on the SERD. Can you just talk about, when you think about registration timelines in the US and the EU, I think we focused a little bit less on the EU. How this strategy will accelerate your timeline in the EU and how quickly if you can use the study, you might be able to get registered in the EU as well?</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Gary Hattersley:</dt> <dd class="flex-auto">Yeah. I think that's an important part of our strategy is to, we see elacestrant as having important global value and so this comparator study, we believe, could be sufficient to support registration, both in the US and EU. So we believe that's actually one of the potential values for the study. Of course comparing to hormonal comparator as well, I think we‚Äôll provide some very compelling information to understand the potential benefits of elacestrant.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Jesper H√∏iland:</dt> <dd class="flex-auto">Matthew, this is Jesper speaking. Just to add on to it, when we discussed with potential partners, we‚Äôve got the insight that they sincerely wanted us to go this way for us to create a partnership, so that we took into consideration and when we learned back from EMEA, we decided that this was the best way forward to create maximum value.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Matthew Harrison:</dt> <dd class="flex-auto">And then second, you mentioned some non-clinical supportive studies that you need to run with the patch, maybe, could you just be a little bit more specific about what those studies are? And then I guess from a manufacturing standpoint, what sort of data and stability you need to provide to the FDA?</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Gary Hattersley:</dt> <dd class="flex-auto">Yeah. Absolutely. So the supportive clinical and clinical study has really fallen to category of being sort of routine part of drug development. So, there are some additional preclinical dermal tolerance studies that we expect to conduct. Certainly, very routine studies, very clear guidance on what is expected for those studies. They're absolutely not rate limiting for our development path. I'm sorry, you had a second part to the question. Oh, stability. So we expect, as is typical to have to have 12 months of stability from our commercial line to be available at the time of NDA submission.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Matthew Harrison:</dt> <dd class="flex-auto">And then sorry one other follow-up that I just wanted to ask, can you just detail in terms of PK data that you have on slide 31, how many patients ‚Äì what was the sample size that you had to generate the AUC exposure, can you have any arrow bars on here, how variable was the response and how confident do you feel in patch to patch variability.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Gary Hattersley:</dt> <dd class="flex-auto">That's actually a great and actually a very important question. So the dataset you're looking at on that slide is derived from 20 patients with our optimized patch. And so from a PK perspective, that's actually quite a rich dataset that does actually give us a very good handle on what the variability of the patch is and I think we're very encouraged to see that that patch variability is in line with what we see with subcutaneous injection and that's even a prepay experience with our prototypes as well. And also that, when we‚Äôve conducted this exposure response analysis, putting this transdermal PK data into that model, one of the things that it looks at is also the inherent variability. So when you see the estimated mean and 95% confidence intervals for the BMD change on I think slide 32, you're actually seeing the integrated effects of variability in that model as well again, which I think gives us high degree of confidence that we have a patch that is suitable to go into the pivotal study with a great probability of success.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-indigo-200" style="flex-basis:0px;">Operator:</dt> <dd class="flex-auto">Our next question comes from Ying Huang with Bank of America Merrill Lynch.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Ying Huang:</dt> <dd class="flex-auto">I have also a couple of quick ones on the patch. First, can you tell us a little bit more about the 20 patient study? Are they all on the patch therefore, you're not comparing directly to any patients on the subcu in the same trial? And secondly besides that AUC, what other PK or PD parameters are you collecting, so that you feel confident about the bioequivalent between the subcu and the patch formulation? Lastly, how confident are you that you will be able to enroll 500 patients in a relatively short period of time so that you can stick to your timeline of 2020 NDA preparation?</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Gary Hattersley:</dt> <dd class="flex-auto">Let me take the last question first. As I think I mentioned a couple of minutes ago, Radius does have a lot of experience in conducting osteoporosis studies, some based on BMD endpoints, some based on fracture end points. So this is a study population that we understand well. We‚Äôve conducted many studies. So, I think we have a very good handle on the enrolment times, the number of sites that we will need, the kinds of sites and the kinds of geographies that we would want to go into. So we have confidence in our ability to conduct this study as quickly as we reasonably can. Your other question was really related to how much PK data have we collected. Really over the last almost 18 months, we've conducted many PK clinical Phase 1 PK studies with multiple iterations and multiple variations with the transdermal patch. There have been many variables that have been assessed and so we've actually had patients that have cycled through several different patch prototypes. We have included periodically subcu injection arms within those studies. So we continue to capture subcu data as part of that. And so when we look at all of that information, I think we're really able to get a good handle on the profile of subcu of course as well as the profile of the optimized patch and it's really let us to a point where we are actually extremely comfortable with the patch that we have, its ability to deliver the profile that we needed to and again it's a patch that we're very, very enthusiastic about seeing moving into a pivotal study.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Ying Huang:</dt> <dd class="flex-auto">Just a quick follow-up. So you had more than 20 patients on this current patch formulation in the Phase 1 trials?</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Gary Hattersley:</dt> <dd class="flex-auto">The dataset you are seeing is derived from 20 patients. There have been a lot more different variations, a number of different iterations of this patch that have been evaluated over the course of the last 18 months.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-indigo-200" style="flex-basis:0px;">Operator:</dt> <dd class="flex-auto">[Operator Instructions] Our next question comes from Salveen Richter with Goldman Sachs.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Kevin Patel:</dt> <dd class="flex-auto">This is Kevin Patel on for Salveen. First question is for the elacestrant compare and controlled study. How long will it take to data? And then the second one is for TYMLOS, you have exclusive status to Express Scripts, so what percentage of Express Scripts patients are you tracking over the quarter and how are you thinking about compliance?</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Gary Hattersley:</dt> <dd class="flex-auto">I will take the elacestrant questions and I think maybe Joe will take the other one. So, at this point, we're actually not guiding in terms of how long it will take us to enroll the elacestrant study. We‚Äôre guiding to when the study would be initiated, which is the first half of -- I'm sorry, second half of 2018. Obviously, it's a high priority for us, we're looking to execute this study as quickly as possible and to enroll as quickly as reasonably possible.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Joe Kelly:</dt> <dd class="flex-auto">So when you look at what ESI represents from a commercial standpoint in the anabolic space, it's about 18%. Looking at total number of lives, there's about 57 million, of which 24 million, we do have preferred status with TYMLOS and right now, we are meeting expectations as far as what we've set as a goal to be at from a market share standpoint and also the goal that we agreed upon with Express Scripts, but we‚Äôll be sure to update you on the next call that we have together, it's a bit early in the game as far as accurate data at the point, but I can say that both sides are satisfied with where we are right now.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Kevin Patel:</dt> <dd class="flex-auto">Just one follow-up, based off of the trends you're seeing now, do you still expect to provide guidance on the 1Q call?</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Pepe Carmona:</dt> <dd class="flex-auto">This is Pepe speaking. So the expectation is that at the end of -- when we present the Q1 earnings call, we will give guidance in certain KPI aspects of the business for full year 2018.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Gary Hattersley:</dt> <dd class="flex-auto">So the answer is yes.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-indigo-200" style="flex-basis:0px;">Operator:</dt> <dd class="flex-auto">And our next question comes from Robyn Karnauskas with Citi.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Greg Harrison:</dt> <dd class="flex-auto">This is Greg Harrison on for Robyn. Thanks for taking my question. With regards to the TYMLOS price increase, what proportion of that increase do you expect to realize and what is your strategy with respect to balancing the price that reflects the value of the drug with also having -- keeping the lower price in Forteo and trying to use that to grow the market to where it had been previously.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Pepe Carmona:</dt> <dd class="flex-auto">This is Pepe speaking. So in terms of what portion of 5.9% goes to net, we haven't guided specifically on that, but we do expect a large portion of it to be reflected in net sales. As always when you have price increases like this and you have contracts with multiple players, you have administration fees, a few things that kick in. So it's going to be a portion of that, but it‚Äôs the larger majority of it. From a pricing strategy perspective, we believe that we will continue to take price increases that are responsible to the market. We need to recall we're obviously cost -- this cost increase is from salaries to FDA fees to other things that we will continue to ensure that those are recovered of the business. We are still about far distance from our competitor on reporting to the market. So we don't see this as diminishing the potential of TYMLOS to continue penetrating and becoming market leader.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Jesper H√∏iland:</dt> <dd class="flex-auto">So Greg, if I may add to it, just because price is of my sincere interest and the price differentiation that you have seen is of course also, you need to think about the potential entry of a biosimilar by end of 2019. So we have put ourselves as a point where we feel we can very much compete with whoever comes into the space at that point of time, because the typical way forward for the biosimilars is of course being to take a 20% to 30% price decrease of the whack and thereby going in and within 180 days skim the market if you will. We are taking a very different price approach because if that's what the biosimilars are going to do, then they will still be in the 30,000 when we are in the early 20,000. So as far as I'm concerned, we are in a very, very strong position going forward with the price point that we have provided on here. So all in all, we will navigate in the space, we have got the market access that we wanted, that's also a very important component of course within 9 months to have 259 million lives to be covered I think speaks for itself and that's of course a part of the pricing strategy that we set up with in the very initial phase.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Greg Harrison:</dt> <dd class="flex-auto">Just one more if I can on the patch trial. So if you were to hit the non-inferiority margin statistically, but still being numerically below subcutaneous, would that be a problem clinically for doctors and for marketing to patients?</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Jesper H√∏iland:</dt> <dd class="flex-auto">We are debating it. We should answer it.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Pepe Carmona:</dt> <dd class="flex-auto">At the end of the day, the bridging studies that was agreed with the FDA for BMD is if we keep that number within that range, so above that threshold, we will have an approved product and obviously it will apply the TYMLOS label to it. Competitive wise, I think those are different questions. I think that‚Äôs -- we will have a better understanding of how we're going to commercialize it later on.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Jesper H√∏iland:</dt> <dd class="flex-auto">And just think about the timelines that we've been up with the patch is very indicative of what -- should be indicative of what will be the thinking for the potential biosimilars entering into the market because we will, with the price point that we have come up with, have strongly indicated that we're going to change the name of the game coming out with a patch. And we're very, very encouraged with the signature of 3M, which happened earlier this week. So all in all, we feel that we are on the right way forward for Radius Health.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-indigo-200" style="flex-basis:0px;">Operator:</dt> <dd class="flex-auto">I‚Äôm showing no further questions at this time. I‚Äôd like to turn the call back over to Jesper H√∏iland for closing remarks.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-yellow-400" style="flex-basis:0px;">Jesper H√∏iland:</dt> <dd class="flex-auto">So thank you very much for your interest in Radius Health. We came out of 2017 with a strong performance. We are continuing with it as far as we are concerned, both with TYMLOS, but certainly also with our way forward for our pipeline. With the signature from 3M and us, we have secured that we have a very strong path going forward to do the Phase 3 clinical trials and we look really forward to report more as the year progresses. So thank you to all of you for your interest and look forward to see you all out there in the front line.</dd></li><li class="b-list-item border-b border-indigo-400 border-opacity-50 py-4 flex flex-col md:flex-row"><dt class="md:min-w-xs md:max-w-xs mr-4 md:text-right text-lg md:text-base font-bold text-indigo-200" style="flex-basis:0px;">Operator:</dt> <dd class="flex-auto">Ladies and gentlemen, this concludes today‚Äôs conference. Thanks for your participation. Have a wonderful day.</dd></li></ul></div></div></div> <div class="b-content content leading-relaxed max-w-2xl xl:max-w-3xl 2xl:max-w-4xl mx-auto mt-8"><ins data-ad-client="ca-pub-9608158334186947" data-ad-layout="in-article" data-ad-slot="9798595324" data-ad-format="fluid" data-adtest="off" data-full-width-responsive="true" class="adsbygoogle" style="display:block;"></ins></div></div></div> <div class="px-4 sm:px-6 md:px-8 w-full max-w-[1444px] mx-auto mb-8 md:mb-12 xl:mb-16"><div class="b-content content leading-relaxed max-w-2xl xl:max-w-3xl 2xl:max-w-4xl mx-auto text-lg nuxt-content"><h2>Other Radius Health, Inc. earnings call transcripts:</h2> <ul><li><a href="/stocks/RDUS/earnings-call-transcripts/225719" class="font-semibold underline text-yellow-400 hover:text-yellow-300">Q2 (2023) RDUS earnings call transcript</a></li><li><a href="/stocks/RDUS/earnings-call-transcripts/225720" class="font-semibold underline text-yellow-400 hover:text-yellow-300">Q1 (2023) RDUS earnings call transcript</a></li><li><a href="/stocks/RDUS/earnings-call-transcripts/225721" class="font-semibold underline text-yellow-400 hover:text-yellow-300">Q4 (2022) RDUS earnings call transcript</a></li><li><a href="/stocks/RDUS/earnings-call-transcripts/225722" class="font-semibold underline text-yellow-400 hover:text-yellow-300">Q3 (2022) RDUS earnings call transcript</a></li><li><a href="/stocks/RDUS/earnings-call-transcripts/225724" class="font-semibold underline text-yellow-400 hover:text-yellow-300">Q2 (2022) RDUS earnings call transcript</a></li><li><a href="/stocks/RDUS/earnings-call-transcripts/154361" class="font-semibold underline text-yellow-400 hover:text-yellow-300">Q1 (2022) RDUS earnings call transcript</a></li><li><a href="/stocks/RDUS/earnings-call-transcripts/136538" class="font-semibold underline text-yellow-400 hover:text-yellow-300">Q4 (2021) RDUS earnings call transcript</a></li><li><a href="/stocks/RDUS/earnings-call-transcripts/126211" class="font-semibold underline text-yellow-400 hover:text-yellow-300">Q3 (2021) RDUS earnings call transcript</a></li><li><a href="/stocks/RDUS/earnings-call-transcripts/126210" class="font-semibold underline text-yellow-400 hover:text-yellow-300">Q2 (2021) RDUS earnings call transcript</a></li><li><a href="/stocks/RDUS/earnings-call-transcripts/56378" class="font-semibold underline text-yellow-400 hover:text-yellow-300">Q1 (2021) RDUS earnings call transcript</a></li></ul></div></div></section></main> <footer role="contentinfo" class=" font-sm pt-8 pb-4 bg-indigo-500 shadow-xl"><div class="px-4 sm:px-6 md:px-8 w-full max-w-[1444px] mx-auto"><div class="grid grid-cols-1 md:grid-cols-3 items-end gap-x-4 gap-y-8"><div class="text-center md:text-left"><div class="mb-3 text-center"><a href="/" class="nuxt-link-active"><img src="/images/logo.svg" width="183" height="32" alt="Strike.Market" class="mx-auto md:ml-0"></a></div> <p class="text-indigo-200">Strike the best investing opportunities on the market!</p></div> <div class="flex justify-center flex-wrap md:justify-start gap-16 2xl:gap-20"><div class="mb-0.5"><h2 class="text-base uppercase text-indigo-200 font-bold mb-3 lg:mb-2">Our company</h2> <ul class="text-sm leading-tight -my-2 lg:-my-0.5 -mx-5 lg:-mx-2"><li><a href="/about-us" class="block lg:inline-block font-bold lg:font-medium hover:bg-indigo-700 lg:hover:bg-transparent py-1 lg:py-0.5 px-5 lg:px-2 text-indigo-50 hover:text-white lg:hover:underline">About us</a></li> <li><a href="/contact" class="block lg:inline-block font-bold lg:font-medium hover:bg-indigo-700 lg:hover:bg-transparent py-1 lg:py-0.5 px-5 lg:px-2 hover:text-white lg:hover:underline">Contact</a></li></ul></div> <div class="mb-0.5"><h2 class="text-base uppercase text-indigo-200 font-bold mb-3 lg:mb-2">Follow us</h2> <ul class="text-sm leading-tight -my-2 lg:-my-0.5 -mx-5 lg:-mx-2"><li><a href="https://twitter.com/strike_market" target="_blank" class="block lg:inline-block font-bold lg:font-medium hover:bg-indigo-700 lg:hover:bg-transparent py-1 lg:py-0.5 px-5 lg:px-2 text-indigo-50 hover:text-white lg:hover:underline">Twitter</a></li></ul></div> <div class="mb-0.5"><h2 class="text-base uppercase text-indigo-200 font-bold mb-3 lg:mb-2">For developers</h2> <ul class="text-sm leading-tight -my-2 lg:-my-0.5 -mx-5 lg:-mx-2"><li><a href="/widgets" class="block lg:inline-block font-bold lg:font-medium hover:bg-indigo-700 lg:hover:bg-transparent py-1 lg:py-0.5 px-5 lg:px-2 text-indigo-50 hover:text-white lg:hover:underline">Widgets</a></li></ul></div></div> <div class="self-end text-center md:text-right"><p class="text-indigo-200 italic tracking-wide text-base md:text-sm mb-5 md:mb-3 max-w-md md:max-w-lg mx-auto md:mr-0">
            Strike.Market does not provide financial advice or recommendations. We are not a&nbsp;trading platform and do not offer to&nbsp;buy stock or sell any security.
          </p> <p class="text-indigo-100 text-base md:text-sm">¬© Ô∏èFlow Media s.r.o. All rights reserved.</p></div></div></div></footer></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at,au,av,aw,ax,ay,az,aA,aB,aC,aD,aE,aF,aG,aH,aI,aJ,aK,aL,aM,aN,aO,aP,aQ,aR,aS,aT,aU,aV,aW,aX,aY,aZ,a_){return {layout:"default",data:[{transcript:{id:56392,companyId:12966,quarter:f,year:2017,content:"Operator: Good day, ladies and gentlemen and welcome to the Radius Health fourth quarter and full year 2017 earnings conference call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to Elhan Webb, Head of Investor Relations. Ma‚Äôam, you may begin.\nElhan Webb: Thank you, Shannon. Good evening, and thank you all for joining us on the conference call and webcast for Radius's fourth quarter and full year 2017 financial results and business update. Joining me today are Jesper H√∏iland, President and Chief Executive Officer; Joe Kelly, our Senior VP of Sales and Marketing; Gary Hattersley, our Chief Scientific Officer; and Pepe Carmona, our Chief Financial Officer. Before we begin, I would like to remind you that statements made during this call that are not historical facts are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the Risk Factors section in our annual report on Form 10-K for the period ended December 31, 2017 and other reports filed with the Securities and Exchange Commission. Any forward-looking statements represent our views as of today, March 1, 2018, only. A replay of this call will be available on the company's website, www.radiuspharm.com. And you can find the dial-in information for the conference call replay in today's press release as well as on the company's website. Today‚Äôs agenda is intended to provide you with a review of what we accomplished in 2017, and update on the TYMLOS launch, our fourth quarter and full year 2017 financials, and update on our development plans for our abaloparatide patch, elacestrant and upcoming corporate milestones. At the end of the call, the management team will be available to answer questions. I'd like to now turn the call over to Jesper H√∏iland, Radius's President and Chief Executive Officer. Jesper?\nJesper H√∏iland: Thank you, Elhan. Welcome everybody and thank you for joining us today. As many of you may already know, we brought on Elhan Webb as our new Head of Investor Relationships and External Communications at the beginning of this year. She comes to us with a considerable global experience, working with both the sell side and buy side analysts as well as her experience as an investment portfolio manager. We are very happy to have Elhan on board. On slide number 5, you will see that Radius achieved a lot in the year of 2017. It has been a transformational year for Radius Health, becoming a fully integrated commercial biopharmaceutical company, committed to bone health and oncology through innovative therapies. A few of our most significant achievements were the FDA approval and subsequent the US commercialization of abaloparatide subcutaneously, named TYMLOS, a bone building agent for the treatment of post-menopausal women with osteoporosis at high risk of fracture. The initiation of our Phase 1 clinical trial for RAD140, a serum for the potential treatment of hormone receptor positive breast cancer and the FDA fast track designation granted for elacestrant, an all investigational search for the treatment of women in metastatic breast cancer. Further, we ended the year with 430 million in cash and the balance sheet strength to support our future growth and plans. We have also built a strong commercial organization to establish TYMLOS leadership. Finally, our successes will not have been possible without the passion and dedication of our talented employees and of course the strong support of our investors, and I want to take this opportunity to thank all of you for your commitment and support. With our new management team in place, we will continue to build on the momentum with several key initiatives underway to accelerate the advancement of our pipeline, establish a strong foundation to maximize our commercial potential, and to continue to build shareholder value. Slide number 6. As you can see, we are well on the way to successfully penetrating the osteoporosis anabolic segment to become the number one leader in the market. Our intention here is to expand further geographically by partnering outside of the US, while we focus our commercial efforts in the US market. We are actively working on expanding and differentiating the TYMLOS label so that we can reach a leadership position in the osteoporosis market. We expect the TYMLOS patch to disrupt and significantly expand the anabolic osteoporosis market as well. Today, we're announcing our path forward for the development of the abaloparatide-patch after the alignment meeting with FDA and our strategic partnership with 3M Company. Gary and I will discuss this more in detail later on in the presentation. In oncology, Radius continued to gain a foothold in breast cancer through Elacestrant, a potential backbone hormonal therapy. Our focus is to initiate a study in third-line therapy and engage in collaboration agreements for the developed and earlier lines of therapy. We will be focused on the commercialization in the US, while partnering outside of the US. Additionally, we will continue to fuel our breast cancer pipeline with RAD140. Today, we are also announcing that based on the feedback from FDA and EMEA, we have decided to initiate the comparator Phase 2 trial potentially a pivotal study to support global registration. We believe, Elacestrant is the leading SERD in the development and has the potential to maximize its value through the global clinical and regulatory pathway. And here on slide number 7, you‚Äôre going to see that we recently announced our commercial leadership changes with the appointment of Joe Kelly as Senior Vice President of Sales and Marketing, and the promotion of Amanda Mott to Senior Vice President of Market Access. Those two will drive the execution of our sales and marketing strategy to best position TYMLOS as the market leader. Joe has over 20 years of experience in sales and marketing in the US, a proven track record in growing billion dollar businesses and successfully launched several products that achieved market leadership. With more than 25 years of an industry experience in the US, Amanda has demonstrated a tremendous knowledge of the payer landscape, and expertise in setting and executing on our market access strategy. She has managed several portfolios in leading pharmaceutical companies and achieved number one market access positions in the US. We hope we will have the opportunity to introduce both of them personally to you in the near future. I will now turn over the call to Joe Kelly to give you a commercial update. Joe?\nJoe Kelly: Thank you, Jesper. And I‚Äôm pleased to provide the full year 2017 TYMLOS performance update, covering the brand in its ninth month of market availability. Our commercial teams remain focused on achieving anabolic market leadership, and throughout the launch process, we kept a strong focus on key opinion leaders and top prescribers in the osteoporosis space where we have gained most of our market share to date. On slide 9, the response to TYMLOS from physicians, payers, and patients has been very positive. Since launching TYMLOS in May of 2017, we've been collecting feedback from anabolic prescribers to gauge their perceptions of the product as compared to other treatment options. As part of our customer surveys, which tracks awareness, trial and usage of TYMLOS amongst targeted physicians, we've learned that current prescribers highlight key attributes of the product, which they perceive as being meaningful and differentiated from other available therapies. These include rapid onset of action and convenience for patients due to carry and storage. On the next slide, I'm also pleased to share that we continue to see growth and manage market access across all segments as coverage increased to 259 million total covered lives. Since the launch of TYMLOS, we see a shifting of the anabolic patient mix towards commercial where TYMLOS coverage in nine months exceeds Forteo‚Äôs after 15 years on the market. For Medicare Part D, products approved after the second quarter are not part of the standard Part D bidding process and require off cycle reviews. We are pleased to report that TYMLOS is already covered for 41% of lives through these off cycle reviews due to its clinical profile combined with savings for patients and this includes coverage on UnitedHealthcare, the nation's largest Medicare Part D insurance plan. We are actively working with our managed care customers on Part D coverage in both off cycle reviews and the 2019 standard bidding process. We look forward to sharing more wins once contracts are finalized. On slide 11, in addition to the exclusive win at ESI that went into effect January 1, TYMLOS is now the preferred anabolic agent on Aetna, Prime and Healthcare Services Corporation also known as HCSC, each having TYMLOS listed as their preferred anabolic for new patients also as of January 1 of this year. Because of these decisions, TYMLOS is now preferred for approximately 30% of the total anabolic volume in commercial. Performance wise, we are capturing patients with the ESI book a business in alignment with expectations and seen growth in the non-ESI and Medicare Part D plans. For 2018, we‚Äôll continue to be focused on market share growth across all segments of business. On the next slide, our top TYMLOS prescribers are coming from our most important customers in the top 200 and tier 1 segments, which make up about 7000 providers. With our strong focus on consistently calling on the highest potential health care providers in osteoporosis, results have been that 88% of TYMLOS business to date is coming from this important tier. We've also built out our promotional speakers‚Äô bureau from 50 key opinion leaders to over 70 who have local, regional and national influence within the osteoporosis space. Slide 13 shows that prior to the second quarter of 2017, the anabolic class has been in decline for five years. What we see now is quarterly volume growth from 3% to 6% over the last three individual quarters. With our efforts across the commercial team and promoting TYMLOS, we are playing a significant part in the growth of the anabolic segment. Also important is when we look across the TYMLOS prescribers, we've found new or returning writers account for 12% of total TYMLOS volume today. Since we are in the early stages of launch, it's too soon to project market and new prescriber growth, but we do see this as encouraging signs of market potential. On slide 14, we're also seeing an acceleration in our ability to acquire new patients as reflected by our NBRx trend, which has more than doubled since the beginning of November of last year. With NBRx being a lead indicator, we expect to see continued anabolic share growth as we improve coverage and get more time with healthcare providers who are active in treating their patients with osteoporosis. In summary, our number one priority is to continue executing the launch of TYMLOS in the US and to establish Radius as the market leader in the anabolic osteoporosis space. We will continue our focus on strong execution by the commercial team and drive TYMLOS market share growth where we have formulary coverage with key commercial and Part D payers. We believe successful in these efforts will drive sustainable growth for the organization, which in turn is beneficial for shareholders and of course the patients we serve. So, thank you. Now, I would like to turn over the call to Pepe Carmona to go over the fourth quarter and 2017 financials.\nPepe Carmona: Thank you, Joe. This is our second quarter full quarter reporting TYMLOS sales. The three months ended December 31, 2017, Radius reported net sales of $7.7 million dollars and a loss of $71 million or $1.59 per share as compared to a net loss of $53 million or $1.22 per share for the three months ended December 31, 2016. The $7.7 million sales figure represents three months of shipments discounted by gross to net adjustments. Our revenue recognition policy is in line with US GAAP and it is described in our Form 10-K On the right side of the slide, we show the figures on non-US GAAP basis, which excludes share-based compensation, intangible asset amortization and non-cash interest from the convertible note. You can see the reconciliation between GAAP and non-GAAP in the appendix. Radius on a non-US GAAP basis for the same period reported a net loss of $61 million or $1.38 per share as compared to a net loss of $45 million or $1.05 per share for the three months ended December 31, 2016. I would like to highlight three points. First, our gross margin was reported at 92%, which includes 5% of royalties. Second, the slight decline in R&D expenses versus Q4 of 2016 is driven by the reduction of the abaloparatide SC study expenses. Last, the SG&A increase is driven by the ramp up in support of TYMLOS commercialization and some back office support functions. We're now a fully staffed commercial company with over 200 sales reps working in the field and approximately 20 MSAs, all working to support TYMLOS. As we have said to you before, we‚Äôre allocating resources in accordance with our strategy, which is to drive TYMLOS growth and continue advancing our pipeline. Turning to slide 17, we show our cash, cash equivalents and marketable securities balance as of December 31, 2017, which was $430 million. In the fourth quarter, we reduced our cash balance by $38 million. Most of the uses of cash was for the TYMLOS commercialization and R&D external expenses related to the ramp-up of the products in our pipeline. We have cash inflows from TYMLOS revenues and from the Teijin deal, from which we recognized the license revenues in Q3 2017, but the actual cash was collected this quarter. Finally, I would like to leave you with a thought that at the end of 2017, Radius is in a strong financial position. We have sufficient capital to fund our key development plans, US commercial and other operational activities. Moving to slide 18, let me quickly show you how we transformed the company throughout the quarters in 2017. You can see that in Q1, we hired most of the commercial organization, which had a full quarter impact into Q2. Then in Q2 of 2017, we launched TYMLOS and started to invest in promotional material, which was fully ramped up by Q3. Then in Q3 of 2017, we started buying material and pay our CRO to prepare the elacestrant phase 2 study. And finally, in Q4, we initiated investments to prepare the male OP study and had some one-off legal IP and swing item costs. We have a fully staffed organization, so you can see that our personnel costs are relatively stable in the last two quarters of the year. I look forward to your questions at the end of the call. With that, I will pass the call to Gary for the update on the clinical pipeline.\nGary Hattersley: Thank you, Pepe. As shown on slide 20, we are continuing to support both lifecycle management for TYMLOS and our oncology programs for elacestrant and RAD140. For TYMLOS, as we've previously guided, we continue to expect a CHMP opinion on our MAA submission in the first half of 2018. We are initiating a male osteoporosis bridging study in the first quarter of 2018, which will be a randomized double-blind placebo-controlled study that would enroll approximately 225 men with osteoporosis. The primary endpoint will be change in lumbar spine BMD at 12 months and pending positive outcome from this study, this data would be the basis for a supplemental NDA submission to seek an expanded TYMLOS label. We are also initiating a short term [indiscernible] clinical study in the first half of 2018 and believe this study will provide important information to enhance our understanding of the early anabolic effects of TYMLOS and the relative contribution of bone remodeling and modeling to its anabolic bone building activity. And today, we will provide a significant update on the development of the abaloparatide patch, following alignment with the FDA and completion of a collaboration and supply agreement with 3M. But first some updates on the clinical development plan for elacestrant. At the recent San Antonio Breast Cancer Symposium in December, we provided a significant update on our ongoing Phase 1 study with elacestrant. In this study, which enrolled a heavily pretreated patient population, we reported a 27% ORR, a 47% CBR and a 5.4 month PFS. Importantly, responses we‚Äôre seeing patients to the previously received fulvestrant, CDK4\u002F6 inhibitors and in patients with ESR1 mutations. Elacestrant was generally well tolerated with the most common adverse events of low grade nausea, dyspepsia and vomiting. We believe this data continues to be strongly supportive of the advancement of elacestrant to potentially pivotal phase 2 study. Before providing details of this study, it‚Äôs important to provide some further context for our data as shown on slide 22. When we look at response rates to hormonal agents in the late line setting, for example with Fulvestrant in the BELLE-3 study, which represents a third line patient population, it was a 2.1% response rate and even in a second line population, in studies like PALOMA-3 and SOFEA, the response rate was less than 10%. Similarly, for PFS, as shown on slide 23, Fulvestrant in the third line setting achieved a 1.8 months PFS and in the second line population, the PFS was less than five months. So based on our five Phase 1 updates at San Antonio in December, we remain very encouraged by the potential for elacestrant. As is typical in clinical development programs, we have recently had further engagement with the FDA around potential pathways to registration and while a single arm study together with a confirmatory study remains an option, our strategy has been to have a pathway that supports both global approval. So we instead intend to conduct a randomized comparator controlled study. This is a well-established part that could support registration for elacestrant as a third line monotherapy. We‚Äôve also engaged the EMA and received feedback for the comparator study may also support EU registration. This study would enroll approximately 300 patients with estrogen-receptor-positive, HER2 negative advanced for metastatic breast cancer that will be randomized to receive either elacestrant or investigator‚Äôs choice to form with PFS as the primary endpoint. We will provide more details on the Phase 2 study when it's initiated, which we expect to occur in the second half of 2018. Based on the emerging clinical and preclinical profile for elacestrant, we see significant opportunities not only in the third line setting, but also in earlier lines of therapy, either as a monotherapy or in combination with other targeted use, a path we intend to pursue through strategic collaboration agreements. At this point, I'd like to switch focus and provide an update on the abaloparatide-patch. We're pleased to report significant progress with our short wear time patch program, which is a key component to extended TYMLOS franchise, which could provide an alternative to self-injection and the potential to enhance patient convenience. Our strategy is to bridge the patch to our proved TYMLOS products based on the BMD study. This is an established pathway to registration in osteoporosis and one that provides important pharmacodynamics, long-term safety and patient experience data for the patch. It's also worth noting that the time line to NDA submission is similar for either a BMD or PK bioequivalent strategy. We've aligned with the FDA on the pathway to support bridging and we have also completed a collaboration to supply agreement with 3M and Jesper will provide more details on this agreement later during this call. So in January, we met with the FDA to discuss the development pathway for the patch. Those agreements on a single, pivotal BMD non-inferiority study, which will be a two arm study with one to one randomization of patients to receive either abaloparatide subcu or the patch and the primary endpoint would be change in lumbar spine BMD at 12 months. Importantly, we have aligned on study power, sample size, and non-inferiority margin as well as on the supportive clinical and non-clinical studies required for NDA submission. We expect this pivotal study to initiate in mid-2019. The non-inferiority margin is based on preserving 75% of the treatment effect of the active comparator based on the lower bound of the 95% confidence interval. So using our Phase 3 active dataset as an example, where the mean change in lumbar spine BMD at 12 months was 9% with a lower bound of 8.5% to preserve 75% of the subcu treatment effect, the BMD 95% confidence interval with a patch would need to be greater than 6.4% to achieve non-inferiority. Our recent focus has been on the continued optimization of the patch to achieve comparability to subcu. As previously reported, our first prototype patch established the suitability and tolerability of this patch technology with over 36,000 individual patch applications made to over 250 patients, but due to the highly positive pharmacokinetic profile of this patch, BMD efficacy was suboptimal compared to subcu. Our second prototype patch introduced formulation technology, which was able to significantly enhance the pharmacokinetic profile with delayed Tmax, extended half-life and increased exposure. We have now completed optimization of the patch, which has been achieved through finalization of the formulation, process optimization, selection of dose and introduction of a new applicator. As shown on slide 31, this optimized patch achieves the target profile by further increasing half-life and exposure relative to earlier prototype patches. And importantly, as shown in the summary of clinical data in the table now achieves the same exposure as subcu. To evaluate the potential for this optimized patch to achieve BMD non-inferiority, we work with a third-party PKPD modeling and simulation company to develop an exposure response relationship model using our extensive Phase 3 active BMD and PK dataset. This approach established a clear relationship between BMD and exposure. So together with our optimized patch data, this allows an estimation of BMD gains and thereby enables an estimation of the probability to achieve non-inferiority. Slide 33 shows the time course of predicted BMD gains at the lumbar spine for subcu in orange and for the optimized patch in green, with both mean and 95% confidence interval values shown. Also shown on the figure is the BMD non-inferiority bar at the 12-month time point. We believe this analysis predicts a high probability of success for the patch to achieve non-inferiority in a 12-month BMD study. At this point, we are continuing to focus on commercial manufacturing scale-up activities for both the patch and the applicator together with the supportive clinical and non-clinical activities in preparation for the pivotal study and NDA. CMC preparation and manufacturing of clinical supplies are now key activities to support the initiation of the pivotal Phase 3 study, which we expect to occur in mid-2019 with study completion in 2020. At this point, I'd like to pass the call over to Jesper to provide comments on the patch opportunity and the collaboration agreements.\nJesper H√∏iland: Thank you, Gary. I'm sure you can appreciate the excitement we at Radius for the development of the patch. We believe it has the potential to disrupt and grow the anabolic market. On slide 35, we like to share with you some of the qualitative research we have performed with patients, physicians and payers. We have received consistent responses that needle avoidance is a significant issue. This limits initiation and continuation of the anabolic therapy. There's a strong preference for pets versus an injection. Patients don't just fear injections per se, they fear by the injections represented, which is a serious illness. Patients would be much more willing to use a non-injectable and anabolic treatment because they feel less sickness and they are willing to confront their condition rather than deny severity. Some physicians notably DCPs who don't currently prescribe injectable anabolics indicated their willingness to prescribe a patch rather than referring the patients to specialists. They felt by providing the option of a patch versus an injection, they would be able to convince many of the high risk osteoporosis patients to start and stay on anabolic therapy and receive bone building benefits. And on slide 36, you can see why we believe the abaloparatide patch, if approved, can change the treatment paradigm and expand the anabolic market significantly. We see a large opportunity to expand the treatment for osteoporosis patients with anabolic therapy, not only to the patients with prior fracture, but also to patients who are at high risk of fracture, all have failed, all become intolerant to other available osteoporosis therapies. For physicians, our analysis reveals that the current -- only 17,000 physicians prescribing anabolics with the majority being specialists. With the introduction of the patch, we will be able to capture high volume osteoporosis prescribers and substantially expand our prescriber base. As you can see on the right side of the slide, anabolics is not the major expenses for the payers. Based on feedback from payers, the patch would be a valuable as it has the potential to improve patient compliance, outcomes and defray practice costs. Patch provides an opportunity to bring innovation and to be appropriately valued in the market. The osteoporosis market is valued at almost $3 billion. We are currently very excited to announce that we have recently entered into the worldwide partnership agreement with 3M for the exclusive manufacturing and supply of the abaloparatide patches and the key terms for the agreement are shown here on slide 37. In collaboration, we will cover certain capital expenditures ensured by 3M to set up the commercial manufacturing facility. After launch, 3M will supply us with coated patches at cost plus basis in a tiered pricing structure and will be entitled to a mid to low single digit royalty on worldwide net sales of the abaloparatide patch. So, to conclude, we are extremely excited to be moving forward with the development of our abaloparatide patch, having achieved an alignment with the regulatory path with FDA and collaboration agreement with 3M, the applied science leading innovator. The abaloparatide patch, if approved, has the potential to provide benefits of bone building therapy to many more osteoporosis patients. We see the patch as an important value driver for Radius, expanding the anabolic market and extending the abaloparatide franchise potentially up to 2037. As you can see on slide 40, we anticipate many inflection points that will significantly impact Radius going forward. So we expect 2018 to be very exciting for Radius with TYMLOS progressing towards market leadership and further advancing our pipeline. I would like to thank you all for your interest and support in Radius Health and I will like to ask that we open for calls now.\nOperator: [Operator Instructions] Our first question comes from Jessica Fye with JP Morgan.\nJessica Fye: I wanted to ask a couple about the elacestrant study. Specifically, can you help us think about what you expect the mix of dealers' choice and the current therapies to be in that trial? And then your patients have seen Aromatase inhibitor early on, potentially a third and the second line, what do you expect them to be randomized to in the control arm of your study? And then in addition, I think you mentioned an interim look in that one. Can you talk about when you project that might occur from a timing standpoint or what number of patients or progression of events would be triggered -- would trigger that interim?\nJesper H√∏iland: Thank you, Jessica. I will have Gary to answer.\nGary Hattersley: At this point, we're not providing guidance on the details of the study. That‚Äôs just something that we will do once the study is initiated in the second half of this year. But certainly when we look at the types of hormonal agents that are used in a late line setting, there are relatively small number of options; and of course, as I think we try to highlight with some of the data here and at San Antonio, when we look at the response rates and the PFS for those hormonal agents in a late line setting, I think we have a very good handle on how they perform and I think it makes us very encouraged that elacestrant really has the potential to perform very well against the comparator, but again we‚Äôll provide more details when the study is initiated. We have guided that we are intending to perform an interim analysis. At this point, we're not providing any further detail around when that patent information may be available.\nJessica Fye: And maybe just following up on that, is there a call in your Phase 1, patients had seen a number of prior therapies, including multiple different endocrine therapies, but should we expect the idea that these patients may have already seen multiple endocrine therapies to pose any enrollment challenges if an investigator might say, I‚Äôd love for you to try 1901 , but not sure you should be trying another product that you might have already failed on for example.\nGary Hattersley: That's a very good question. We know in this late line setting, as you described, many of these patients will have progressed through several hormonal therapies earlier in treatments. It's not uncommon for hormonal agents to be reintroduced in a late line. Obviously, these patients have relatively few treatment options on certainly I think when we think about how elacestrant could perform in this late line setting or how we've seen it perform in our ongoing phase 1 study, again against patients that have previously received these endocrine agents, I think we feel very encouraged by Elacestrant‚Äôs potential.\nJessica Fye: And maybe just last one on the patch study. Can you talk about your assumptions for enrolment? I just want to make sure I understand, as you're starting the study in mid-19 and expect to see data on a 12-month endpoint in 2020. Is it fair to imply you expect to get 500 patients enrolled in six months?\nGary Hattersley: Obviously, we're not providing specific guidance around enrolment. Certainly, Radius has a long history of conducting many BMD studies through the course of development for abaloparatide. So, I think we have a very good handle on what it would take to enroll these patients, how many sites that we would expect to be able to enroll these patients quickly. We certainly think with the study design in which patients are going to receive either the subcutaneous injection or the abaloparatide patch that this could be quite a -- study of patients may be enthusiastic about taking part in.\nJessica Fye: Forgive me, but just one more on the patch, can you just talk a little bit more about how you got comfortable or convinced that the BMD effect is really AUC driven and not affected by the shape of the curve, now that it looks like you're very close on AUC but have moved away on Cmax and Tmax.\nGary Hattersley: Yeah. So the Cmax and the Tmax is the same -- within the target for subcutaneous injection, but it's really heavily driven by our experience with our active Phase 3 dataset. That is a very rich dataset in which we have several thousand PK data points as well as we have BMD values from a large number of patients across multiple time points. That's really been a data set that‚Äôs allowed us to construct this exposure response model to be able to look at multiple PK parameters, and I think our analysis, where we input the transdermal patch data into that model gives us a very high degree of confidence that the patch we have right now is optimized patch, has the profile that it needs to be able to achieve the BMD endpoints and to be successful in a non-inferiority BMD study.\nOperator: Our next question comes from Matthew Harrison with Morgan Stanley.\nMatthew Harrison: I think maybe two from me. So first on the SERD. Can you just talk about, when you think about registration timelines in the US and the EU, I think we focused a little bit less on the EU. How this strategy will accelerate your timeline in the EU and how quickly if you can use the study, you might be able to get registered in the EU as well?\nGary Hattersley: Yeah. I think that's an important part of our strategy is to, we see elacestrant as having important global value and so this comparator study, we believe, could be sufficient to support registration, both in the US and EU. So we believe that's actually one of the potential values for the study. Of course comparing to hormonal comparator as well, I think we‚Äôll provide some very compelling information to understand the potential benefits of elacestrant.\nJesper H√∏iland: Matthew, this is Jesper speaking. Just to add on to it, when we discussed with potential partners, we‚Äôve got the insight that they sincerely wanted us to go this way for us to create a partnership, so that we took into consideration and when we learned back from EMEA, we decided that this was the best way forward to create maximum value.\nMatthew Harrison: And then second, you mentioned some non-clinical supportive studies that you need to run with the patch, maybe, could you just be a little bit more specific about what those studies are? And then I guess from a manufacturing standpoint, what sort of data and stability you need to provide to the FDA?\nGary Hattersley: Yeah. Absolutely. So the supportive clinical and clinical study has really fallen to category of being sort of routine part of drug development. So, there are some additional preclinical dermal tolerance studies that we expect to conduct. Certainly, very routine studies, very clear guidance on what is expected for those studies. They're absolutely not rate limiting for our development path. I'm sorry, you had a second part to the question. Oh, stability. So we expect, as is typical to have to have 12 months of stability from our commercial line to be available at the time of NDA submission.\nMatthew Harrison: And then sorry one other follow-up that I just wanted to ask, can you just detail in terms of PK data that you have on slide 31, how many patients ‚Äì what was the sample size that you had to generate the AUC exposure, can you have any arrow bars on here, how variable was the response and how confident do you feel in patch to patch variability.\nGary Hattersley: That's actually a great and actually a very important question. So the dataset you're looking at on that slide is derived from 20 patients with our optimized patch. And so from a PK perspective, that's actually quite a rich dataset that does actually give us a very good handle on what the variability of the patch is and I think we're very encouraged to see that that patch variability is in line with what we see with subcutaneous injection and that's even a prepay experience with our prototypes as well. And also that, when we‚Äôve conducted this exposure response analysis, putting this transdermal PK data into that model, one of the things that it looks at is also the inherent variability. So when you see the estimated mean and 95% confidence intervals for the BMD change on I think slide 32, you're actually seeing the integrated effects of variability in that model as well again, which I think gives us high degree of confidence that we have a patch that is suitable to go into the pivotal study with a great probability of success.\nOperator: Our next question comes from Ying Huang with Bank of America Merrill Lynch.\nYing Huang: I have also a couple of quick ones on the patch. First, can you tell us a little bit more about the 20 patient study? Are they all on the patch therefore, you're not comparing directly to any patients on the subcu in the same trial? And secondly besides that AUC, what other PK or PD parameters are you collecting, so that you feel confident about the bioequivalent between the subcu and the patch formulation? Lastly, how confident are you that you will be able to enroll 500 patients in a relatively short period of time so that you can stick to your timeline of 2020 NDA preparation?\nGary Hattersley: Let me take the last question first. As I think I mentioned a couple of minutes ago, Radius does have a lot of experience in conducting osteoporosis studies, some based on BMD endpoints, some based on fracture end points. So this is a study population that we understand well. We‚Äôve conducted many studies. So, I think we have a very good handle on the enrolment times, the number of sites that we will need, the kinds of sites and the kinds of geographies that we would want to go into. So we have confidence in our ability to conduct this study as quickly as we reasonably can. Your other question was really related to how much PK data have we collected. Really over the last almost 18 months, we've conducted many PK clinical Phase 1 PK studies with multiple iterations and multiple variations with the transdermal patch. There have been many variables that have been assessed and so we've actually had patients that have cycled through several different patch prototypes. We have included periodically subcu injection arms within those studies. So we continue to capture subcu data as part of that. And so when we look at all of that information, I think we're really able to get a good handle on the profile of subcu of course as well as the profile of the optimized patch and it's really let us to a point where we are actually extremely comfortable with the patch that we have, its ability to deliver the profile that we needed to and again it's a patch that we're very, very enthusiastic about seeing moving into a pivotal study.\nYing Huang: Just a quick follow-up. So you had more than 20 patients on this current patch formulation in the Phase 1 trials?\nGary Hattersley: The dataset you are seeing is derived from 20 patients. There have been a lot more different variations, a number of different iterations of this patch that have been evaluated over the course of the last 18 months.\nOperator: [Operator Instructions] Our next question comes from Salveen Richter with Goldman Sachs.\nKevin Patel: This is Kevin Patel on for Salveen. First question is for the elacestrant compare and controlled study. How long will it take to data? And then the second one is for TYMLOS, you have exclusive status to Express Scripts, so what percentage of Express Scripts patients are you tracking over the quarter and how are you thinking about compliance?\nGary Hattersley: I will take the elacestrant questions and I think maybe Joe will take the other one. So, at this point, we're actually not guiding in terms of how long it will take us to enroll the elacestrant study. We‚Äôre guiding to when the study would be initiated, which is the first half of -- I'm sorry, second half of 2018. Obviously, it's a high priority for us, we're looking to execute this study as quickly as possible and to enroll as quickly as reasonably possible.\nJoe Kelly: So when you look at what ESI represents from a commercial standpoint in the anabolic space, it's about 18%. Looking at total number of lives, there's about 57 million, of which 24 million, we do have preferred status with TYMLOS and right now, we are meeting expectations as far as what we've set as a goal to be at from a market share standpoint and also the goal that we agreed upon with Express Scripts, but we‚Äôll be sure to update you on the next call that we have together, it's a bit early in the game as far as accurate data at the point, but I can say that both sides are satisfied with where we are right now.\nKevin Patel: Just one follow-up, based off of the trends you're seeing now, do you still expect to provide guidance on the 1Q call?\nPepe Carmona: This is Pepe speaking. So the expectation is that at the end of -- when we present the Q1 earnings call, we will give guidance in certain KPI aspects of the business for full year 2018.\nGary Hattersley: So the answer is yes.\nOperator: And our next question comes from Robyn Karnauskas with Citi.\nGreg Harrison: This is Greg Harrison on for Robyn. Thanks for taking my question. With regards to the TYMLOS price increase, what proportion of that increase do you expect to realize and what is your strategy with respect to balancing the price that reflects the value of the drug with also having -- keeping the lower price in Forteo and trying to use that to grow the market to where it had been previously.\nPepe Carmona: This is Pepe speaking. So in terms of what portion of 5.9% goes to net, we haven't guided specifically on that, but we do expect a large portion of it to be reflected in net sales. As always when you have price increases like this and you have contracts with multiple players, you have administration fees, a few things that kick in. So it's going to be a portion of that, but it‚Äôs the larger majority of it. From a pricing strategy perspective, we believe that we will continue to take price increases that are responsible to the market. We need to recall we're obviously cost -- this cost increase is from salaries to FDA fees to other things that we will continue to ensure that those are recovered of the business. We are still about far distance from our competitor on reporting to the market. So we don't see this as diminishing the potential of TYMLOS to continue penetrating and becoming market leader.\nJesper H√∏iland: So Greg, if I may add to it, just because price is of my sincere interest and the price differentiation that you have seen is of course also, you need to think about the potential entry of a biosimilar by end of 2019. So we have put ourselves as a point where we feel we can very much compete with whoever comes into the space at that point of time, because the typical way forward for the biosimilars is of course being to take a 20% to 30% price decrease of the whack and thereby going in and within 180 days skim the market if you will. We are taking a very different price approach because if that's what the biosimilars are going to do, then they will still be in the 30,000 when we are in the early 20,000. So as far as I'm concerned, we are in a very, very strong position going forward with the price point that we have provided on here. So all in all, we will navigate in the space, we have got the market access that we wanted, that's also a very important component of course within 9 months to have 259 million lives to be covered I think speaks for itself and that's of course a part of the pricing strategy that we set up with in the very initial phase.\nGreg Harrison: Just one more if I can on the patch trial. So if you were to hit the non-inferiority margin statistically, but still being numerically below subcutaneous, would that be a problem clinically for doctors and for marketing to patients?\nJesper H√∏iland: We are debating it. We should answer it.\nPepe Carmona: At the end of the day, the bridging studies that was agreed with the FDA for BMD is if we keep that number within that range, so above that threshold, we will have an approved product and obviously it will apply the TYMLOS label to it. Competitive wise, I think those are different questions. I think that‚Äôs -- we will have a better understanding of how we're going to commercialize it later on.\nJesper H√∏iland: And just think about the timelines that we've been up with the patch is very indicative of what -- should be indicative of what will be the thinking for the potential biosimilars entering into the market because we will, with the price point that we have come up with, have strongly indicated that we're going to change the name of the game coming out with a patch. And we're very, very encouraged with the signature of 3M, which happened earlier this week. So all in all, we feel that we are on the right way forward for Radius Health.\nOperator: I‚Äôm showing no further questions at this time. I‚Äôd like to turn the call back over to Jesper H√∏iland for closing remarks.\nJesper H√∏iland: So thank you very much for your interest in Radius Health. We came out of 2017 with a strong performance. We are continuing with it as far as we are concerned, both with TYMLOS, but certainly also with our way forward for our pipeline. With the signature from 3M and us, we have secured that we have a very strong path going forward to do the Phase 3 clinical trials and we look really forward to report more as the year progresses. So thank you to all of you for your interest and look forward to see you all out there in the front line.\nOperator: Ladies and gentlemen, this concludes today‚Äôs conference. Thanks for your participation. Have a wonderful day.",date:"2018-03-02 17:00:00",createdAt:y,updatedAt:y,otherTranscripts:[{id:225719,quarter:e,year:z},{id:225720,quarter:b,year:z},{id:225721,quarter:f,year:i},{id:225722,quarter:j,year:i},{id:225724,quarter:e,year:i},{id:154361,quarter:b,year:i},{id:136538,quarter:f,year:k},{id:126211,quarter:j,year:k},{id:126210,quarter:e,year:k},{id:56378,quarter:b,year:k}]},company:{symbol:"RDUS",price:27.52,website:"https:\u002F\u002Fradiuspharm.com",mktCap:d,sharesOutstanding:47342199,name:"Radius Health, Inc.",currency:"USD",cik:"0001428522",isin:"US7504692077",cusip:"750469207",exchangeShortName:"NASDAQ",description:"Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.",industry:"Drug Manufacturers‚ÄîSpecialty & Generic",sector:"Healthcare",country:A,fullTimeEmployees:293,phone:"16175514000",address:"950 Winter St",city:"Waltham",state:"MASSACHUSETTS",zip:"02210",image:"https:\u002F\u002Ffinancialmodelingprep.com\u002Fimage-stock\u002FRDUS.jpg",isFounderLed:g,ipoDate:"2014-06-06",updatedAt:"2023-10-08 22:15:07.615923+00"}}],fetch:{"0":{mobileMenu:g,showNavbar:B,lastScrollPosition:d,isMarketDropdownVisible:g,isStockScreenerDropdownVisible:g,isAcademyDropdownVisible:g}},error:a,state:{user:{watchlist:{list:[],newTickers:[],newFunds:[]},feed:{},calendar:{}},staticData:{metricTypes:{APP_DOWNLOADS_COUNT:b,FOLLOWERS_COUNT:e,JOB_OPENINGS_COUNT:j,EMPLOYEES_COUNT:f,WEB_TRAFFIC:c,APP_RANK:n,APP_RANK_ANDROID_WEAR:o,APP_RANK_ART_AND_DESIGN:p,APP_RANK_AUTO_AND_VEHICLES:q,APP_RANK_BEAUTY:r,APP_RANK_BOOKS_AND_REFERENCE:s,APP_RANK_BUSINESS:t,APP_RANK_COMICS:u,APP_RANK_COMMUNICATION:v,APP_RANK_DATING:C,APP_RANK_EDUCATION:w,APP_RANK_ENTERTAINMENT:D,APP_RANK_EVENTS:E,APP_RANK_FINANCE:F,APP_RANK_FOOD_AND_DRINK:x,APP_RANK_HEALTH_AND_FITNESS:G,APP_RANK_HOUSE_AND_HOME:H,APP_RANK_LIBRARIES_AND_DEMO:I,APP_RANK_LIFESTYLE:J,APP_RANK_APP_WALLPAPER:K,APP_RANK_MAPS_AND_NAVIGATION:L,APP_RANK_MEDIA_AND_VIDEO:M,APP_RANK_MEDICAL:N,APP_RANK_MUSIC_AND_AUDIO:O,APP_RANK_NEWS_AND_MAGAZINES:P,APP_RANK_PARENTING:Q,APP_RANK_PERSONALIZATION:R,APP_RANK_PHOTOGRAPHY:S,APP_RANK_PRODUCTIVITY:T,APP_RANK_SHOPPING:U,APP_RANK_SOCIAL:V,APP_RANK_SPORTS:W,APP_RANK_TOOLS:X,APP_RANK_TRANSPORTATION:Y,APP_RANK_TRAVEL_AND_LOCAL:Z,APP_RANK_VIDEO_PLAYERS:_,APP_RANK_WEATHER:$,APP_RANK_APP_WIDGETS:aa,APP_RANK_GAME:ab,APP_RANK_FAMILY:ac,APP_RANK_GAME_ACTION:ad,APP_RANK_GAME_ADVENTURE:ae,APP_RANK_GAME_ARCADE:af,APP_RANK_GAME_BOARD:ag,APP_RANK_GAME_CARD:ah,APP_RANK_GAME_CASINO:ai,APP_RANK_GAME_CASUAL:aj,APP_RANK_GAME_EDUCATIONAL:ak,APP_RANK_GAME_MUSIC:al,APP_RANK_GAME_PUZZLE:am,APP_RANK_GAME_RACING:an,APP_RANK_GAME_ROLE_PLAYING:ao,APP_RANK_GAME_SIMULATION:ap,APP_RANK_GAME_SPORTS:aq,APP_RANK_GAME_STRATEGY:ar,APP_RANK_GAME_TRIVIA:as,APP_RANK_GAME_WORD:62,APP_RANK_FAMILY_ACTION:at,APP_RANK_FAMILY_BRAINGAMES:au,APP_RANK_FAMILY_CREATE:av,APP_RANK_FAMILY_EDUCATION:aw,APP_RANK_FAMILY_MUSICVIDEO:ax,APP_RANK_FAMILY_PRETEND:ay,APP_RANK_UTILITIES:az,APP_RANK_TRAVEL:aA,APP_RANK_SOCIAL_NETWORKING:aB,APP_RANK_REFERENCE:aC,APP_RANK_PHOTO_VIDEO:aD,APP_RANK_NEWS:aE,APP_RANK_NAVIGATION:aF,APP_RANK_MUSIC:aG,APP_RANK_HEALTH_FITNESS:aH,APP_RANK_GAMES:aI,APP_RANK_NEWSSTAND:aJ,APP_RANK_CATALOGS:aK,APP_RANK_FOOD_DRINK:aL,APP_RANK_GAME_DICE:aM,APP_RANK_GAME_FAMILY:aN,APP_RANK_GAME_KIDS:aO,GOOGLE_TREND:aP,JOB_COUNT:aQ,APP_RANK_BOOKS:aR,SHARE_OF_SEARCH:aS,APP_RANK_DEVELOPER_TOOLS:aT,APP_RANK_APPLICATION:aU},metricTypesById:{"1":"APP_DOWNLOADS_COUNT","2":aV,"3":aW,"4":"EMPLOYEES_COUNT","5":aX,"6":aY,"7":"APP_RANK_ANDROID_WEAR","8":"APP_RANK_ART_AND_DESIGN","9":"APP_RANK_AUTO_AND_VEHICLES","10":"APP_RANK_BEAUTY","11":"APP_RANK_BOOKS_AND_REFERENCE","12":"APP_RANK_BUSINESS","13":"APP_RANK_COMICS","14":"APP_RANK_COMMUNICATION","15":"APP_RANK_DATING","16":"APP_RANK_EDUCATION","17":"APP_RANK_ENTERTAINMENT","18":"APP_RANK_EVENTS","19":"APP_RANK_FINANCE","20":"APP_RANK_FOOD_AND_DRINK","21":"APP_RANK_HEALTH_AND_FITNESS","22":"APP_RANK_HOUSE_AND_HOME","23":"APP_RANK_LIBRARIES_AND_DEMO","24":"APP_RANK_LIFESTYLE","25":"APP_RANK_APP_WALLPAPER","26":"APP_RANK_MAPS_AND_NAVIGATION","27":"APP_RANK_MEDIA_AND_VIDEO","28":"APP_RANK_MEDICAL","29":"APP_RANK_MUSIC_AND_AUDIO","30":"APP_RANK_NEWS_AND_MAGAZINES","31":"APP_RANK_PARENTING","32":"APP_RANK_PERSONALIZATION","33":"APP_RANK_PHOTOGRAPHY","34":"APP_RANK_PRODUCTIVITY","35":"APP_RANK_SHOPPING","36":"APP_RANK_SOCIAL","37":"APP_RANK_SPORTS","38":"APP_RANK_TOOLS","39":"APP_RANK_TRANSPORTATION","40":"APP_RANK_TRAVEL_AND_LOCAL","41":"APP_RANK_VIDEO_PLAYERS","42":"APP_RANK_WEATHER","43":"APP_RANK_APP_WIDGETS","44":"APP_RANK_GAME","45":"APP_RANK_FAMILY","46":"APP_RANK_GAME_ACTION","47":"APP_RANK_GAME_ADVENTURE","48":"APP_RANK_GAME_ARCADE","49":"APP_RANK_GAME_BOARD","50":"APP_RANK_GAME_CARD","51":"APP_RANK_GAME_CASINO","52":"APP_RANK_GAME_CASUAL","53":"APP_RANK_GAME_EDUCATIONAL","54":"APP_RANK_GAME_MUSIC","55":"APP_RANK_GAME_PUZZLE","56":"APP_RANK_GAME_RACING","57":"APP_RANK_GAME_ROLE_PLAYING","58":"APP_RANK_GAME_SIMULATION","59":"APP_RANK_GAME_SPORTS","60":"APP_RANK_GAME_STRATEGY","61":"APP_RANK_GAME_TRIVIA","62":"APP_RANK_GAME_WORD","63":"APP_RANK_FAMILY_ACTION","64":"APP_RANK_FAMILY_BRAINGAMES","65":"APP_RANK_FAMILY_CREATE","66":"APP_RANK_FAMILY_EDUCATION","67":"APP_RANK_FAMILY_MUSICVIDEO","68":"APP_RANK_FAMILY_PRETEND","69":"APP_RANK_UTILITIES","70":"APP_RANK_TRAVEL","71":"APP_RANK_SOCIAL_NETWORKING","72":"APP_RANK_REFERENCE","73":"APP_RANK_PHOTO_VIDEO","74":"APP_RANK_NEWS","75":"APP_RANK_NAVIGATION","76":"APP_RANK_MUSIC","77":"APP_RANK_HEALTH_FITNESS","78":"APP_RANK_GAMES","79":"APP_RANK_NEWSSTAND","80":"APP_RANK_CATALOGS","81":"APP_RANK_FOOD_DRINK","82":"APP_RANK_GAME_DICE","83":"APP_RANK_GAME_FAMILY","84":"APP_RANK_GAME_KIDS","85":aZ,"86":"JOB_COUNT","87":"APP_RANK_BOOKS","88":"SHARE_OF_SEARCH","89":"APP_RANK_DEVELOPER_TOOLS","90":"APP_RANK_APPLICATION"},countriesById:[,{code2:"**",name:"*",id:b},{code2:"AF",name:"Afghanistan",id:e},{code2:"AL",name:"Albania",id:j},{code2:"DZ",name:"Algeria",id:f},{code2:"AS",name:"American Samoa",id:c},{code2:"AD",name:"Andorra",id:n},{code2:"AO",name:"Angola",id:o},{code2:"AI",name:"Anguilla",id:p},{code2:"AQ",name:"Antarctica",id:q},{code2:"AG",name:"Antigua and Barbuda",id:r},{code2:"AR",name:"Argentina",id:s},{code2:"AM",name:"Armenia",id:t},{code2:"AW",name:"Aruba",id:u},{code2:"AU",name:"Australia",id:v},{code2:"AT",name:"Austria",id:C},{code2:"AZ",name:"Azerbaijan",id:w},{code2:"BS",name:"Bahamas",id:D},{code2:"BH",name:"Bahrain",id:E},{code2:"BD",name:"Bangladesh",id:F},{code2:"BB",name:"Barbados",id:x},{code2:"BY",name:"Belarus",id:G},{code2:"BE",name:"Belgium",id:H},{code2:"BZ",name:"Belize",id:I},{code2:"BJ",name:"Benin",id:J},{code2:"BM",name:"Bermuda",id:K},{code2:"BT",name:"Bhutan",id:L},{code2:"BO",name:"Bolivia",id:M},{code2:"BA",name:"Bosnia and Herzegowina",id:N},{code2:"BW",name:"Botswana",id:O},{code2:"BV",name:"Bouvet Island",id:P},{code2:"BR",name:"Brazil",id:Q},{code2:"IO",name:"British Indian Ocean Territory",id:R},{code2:"BN",name:"Brunei Darussalam",id:S},{code2:"BG",name:"Bulgaria",id:T},{code2:"BF",name:"Burkina Faso",id:U},{code2:"BI",name:"Burundi",id:V},{code2:"KH",name:"Cambodia",id:W},{code2:"CM",name:"Cameroon",id:X},{code2:"CA",name:"Canada",id:Y},{code2:"CV",name:"Cape Verde",id:Z},{code2:"KY",name:"Cayman Islands",id:_},{code2:"CF",name:"Central African Republic",id:$},{code2:"TD",name:"Chad",id:aa},{code2:"CL",name:"Chile",id:ab},{code2:"CN",name:"China",id:ac},{code2:"CX",name:"Christmas Island",id:ad},{code2:"CC",name:"Cocos (Keeling) Islands",id:ae},{code2:"CO",name:"Colombia",id:af},{code2:"KM",name:"Comoros",id:ag},{code2:"CG",name:"Congo",id:ah},{code2:"CK",name:"Cook Islands",id:ai},{code2:"CR",name:"Costa Rica",id:aj},{code2:"CI",name:"Cote D'Ivoire",id:ak},{code2:"HR",name:"Croatia",id:al},{code2:"CU",name:"Cuba",id:am},{code2:"CY",name:"Cyprus",id:an},{code2:"CZ",name:"Czech Republic",id:ao},{code2:"DK",name:"Denmark",id:ap},{code2:"DJ",name:"Djibouti",id:aq},{code2:"DM",name:"Dominica",id:ar},{code2:"DO",name:"Dominican Republic",id:as},,{code2:"EC",name:"Ecuador",id:at},{code2:"EG",name:"Egypt",id:au},{code2:"SV",name:"El Salvador",id:av},{code2:"GQ",name:"Equatorial Guinea",id:aw},{code2:"ER",name:"Eritrea",id:ax},{code2:"EE",name:"Estonia",id:ay},{code2:"ET",name:"Ethiopia",id:az},{code2:"FK",name:"Falkland Islands (Malvinas)",id:aA},{code2:"FO",name:"Faroe Islands",id:aB},{code2:"FJ",name:"Fiji",id:aC},{code2:"FI",name:"Finland",id:aD},{code2:"FR",name:"France",id:aE},{code2:"FX",name:"France, Metropolitan",id:aF},{code2:"GF",name:"French Guiana",id:aG},{code2:"PF",name:"French Polynesia",id:aH},{code2:"TF",name:"French Southern Territories",id:aI},{code2:"GA",name:"Gabon",id:aJ},{code2:"GM",name:"Gambia",id:aK},{code2:"GE",name:"Georgia",id:aL},{code2:"DE",name:"Germany",id:aM},{code2:"GH",name:"Ghana",id:aN},{code2:"GI",name:"Gibraltar",id:aO},{code2:"GR",name:"Greece",id:aP},{code2:"GL",name:"Greenland",id:aQ},{code2:"GD",name:"Grenada",id:aR},{code2:"GP",name:"Guadeloupe",id:aS},{code2:"GU",name:"Guam",id:aT},{code2:"GT",name:"Guatemala",id:aU},{code2:"GN",name:"Guinea",id:91},{code2:"GW",name:"Guinea-bissau",id:92},{code2:"GY",name:"Guyana",id:93},{code2:"HT",name:"Haiti",id:94},{code2:"HM",name:"Heard and Mc Donald Islands",id:95},{code2:"HN",name:"Honduras",id:96},{code2:"HK",name:"Hong Kong",id:97},{code2:"HU",name:"Hungary",id:98},{code2:"IS",name:"Iceland",id:99},{code2:"IN",name:"India",id:100},{code2:"ID",name:"Indonesia",id:101},{code2:"IR",name:"Iran (Islamic Republic of)",id:102},{code2:"IQ",name:"Iraq",id:103},{code2:"IE",name:"Ireland",id:104},{code2:"IL",name:"Israel",id:105},{code2:"IT",name:"Italy",id:106},{code2:"JM",name:"Jamaica",id:107},{code2:"JP",name:"Japan",id:108},{code2:"JO",name:"Jordan",id:109},{code2:"KZ",name:"Kazakhstan",id:110},{code2:"KE",name:"Kenya",id:111},{code2:"KI",name:"Kiribati",id:112},{code2:"KP",name:"Korea, Democratic People's Republic of",id:113},{code2:"KR",name:"Korea, Republic of",id:114},{code2:"KW",name:"Kuwait",id:115},{code2:"KG",name:"Kyrgyzstan",id:116},{code2:"LA",name:"Lao People's Democratic Republic",id:117},{code2:"LV",name:"Latvia",id:118},{code2:"LB",name:"Lebanon",id:119},{code2:"LS",name:"Lesotho",id:120},{code2:"LR",name:"Liberia",id:121},{code2:"LY",name:"Libyan Arab Jamahiriya",id:122},{code2:"LI",name:"Liechtenstein",id:123},{code2:"LT",name:"Lithuania",id:124},{code2:"LU",name:"Luxembourg",id:125},{code2:"MO",name:"Macau",id:126},{code2:"MK",name:"Macedonia",id:127},{code2:"MG",name:"Madagascar",id:128},{code2:"MW",name:"Malawi",id:129},{code2:"MY",name:"Malaysia",id:130},{code2:"MV",name:"Maldives",id:131},{code2:"ML",name:"Mali",id:132},{code2:"MT",name:"Malta",id:133},{code2:"MH",name:"Marshall Islands",id:134},{code2:"MQ",name:"Martinique",id:135},{code2:"MR",name:"Mauritania",id:136},{code2:"MU",name:"Mauritius",id:137},{code2:"YT",name:"Mayotte",id:138},{code2:"MX",name:"Mexico",id:139},{code2:"FM",name:"Micronesia, Federated States of",id:140},{code2:"MD",name:"Moldova, Republic of",id:141},{code2:"MC",name:"Monaco",id:142},{code2:"MN",name:"Mongolia",id:143},{code2:"MS",name:"Montserrat",id:144},{code2:"MA",name:"Morocco",id:145},{code2:"MZ",name:"Mozambique",id:146},{code2:"MM",name:"Myanmar",id:147},{code2:"NA",name:"Namibia",id:148},{code2:"NR",name:"Nauru",id:149},{code2:"NP",name:"Nepal",id:150},{code2:"NL",name:"Netherlands",id:151},{code2:"AN",name:"Netherlands Antilles",id:152},{code2:"NC",name:"New Caledonia",id:153},{code2:"NZ",name:"New Zealand",id:154},{code2:"NI",name:"Nicaragua",id:155},{code2:"NE",name:"Niger",id:156},{code2:"NG",name:"Nigeria",id:157},{code2:"NU",name:"Niue",id:158},{code2:"NF",name:"Norfolk Island",id:159},{code2:"MP",name:"Northern Mariana Islands",id:160},{code2:"NO",name:"Norway",id:161},{code2:"OM",name:"Oman",id:162},{code2:"PK",name:"Pakistan",id:163},{code2:"PW",name:"Palau",id:164},{code2:"PA",name:"Panama",id:165},{code2:"PG",name:"Papua New Guinea",id:166},{code2:"PY",name:"Paraguay",id:167},{code2:"PE",name:"Peru",id:168},{code2:"PH",name:"Philippines",id:169},{code2:"PN",name:"Pitcairn",id:170},{code2:"PL",name:"Poland",id:171},{code2:"PT",name:"Portugal",id:172},{code2:"PR",name:"Puerto Rico",id:173},{code2:"QA",name:"Qatar",id:174},{code2:"RE",name:"Reunion",id:175},{code2:"RO",name:"Romania",id:176},{code2:"RU",name:"Russian Federation",id:177},{code2:"RW",name:"Rwanda",id:178},{code2:"KN",name:"Saint Kitts and Nevis",id:179},{code2:"LC",name:"Saint Lucia",id:180},{code2:"VC",name:"Saint Vincent and the Grenadines",id:181},{code2:"WS",name:"Samoa",id:182},{code2:"SM",name:"San Marino",id:183},{code2:"ST",name:"Sao Tome and Principe",id:184},{code2:"SA",name:"Saudi Arabia",id:185},{code2:"SN",name:"Senegal",id:186},{code2:"SC",name:"Seychelles",id:187},{code2:"SL",name:"Sierra Leone",id:188},{code2:"SG",name:"Singapore",id:189},{code2:"SK",name:"Slovakia (Slovak Republic)",id:190},{code2:"SI",name:"Slovenia",id:191},{code2:"SB",name:"Solomon Islands",id:192},{code2:"SO",name:"Somalia",id:193},{code2:"ZA",name:"South Africa",id:194},{code2:"GS",name:"South Georgia and the South Sandwich Islands",id:195},{code2:"ES",name:"Spain",id:196},{code2:"LK",name:"Sri Lanka",id:197},{code2:"SH",name:"St. Helena",id:198},{code2:"PM",name:"St. Pierre and Miquelon",id:199},{code2:"SD",name:"Sudan",id:200},{code2:"SR",name:"Suriname",id:201},{code2:"SJ",name:"Svalbard and Jan Mayen Islands",id:202},{code2:"SZ",name:"Swaziland",id:203},{code2:"SE",name:"Sweden",id:204},{code2:"CH",name:"Switzerland",id:205},{code2:"SY",name:"Syrian Arab Republic",id:206},{code2:"TW",name:"Taiwan",id:207},{code2:"TJ",name:"Tajikistan",id:208},{code2:"TZ",name:"Tanzania, United Republic of",id:209},{code2:"TH",name:"Thailand",id:210},{code2:"TG",name:"Togo",id:211},{code2:"TK",name:"Tokelau",id:212},{code2:"TO",name:"Tonga",id:213},{code2:"TT",name:"Trinidad and Tobago",id:214},{code2:"TN",name:"Tunisia",id:215},{code2:"TR",name:"Turkey",id:216},{code2:"TM",name:"Turkmenistan",id:217},{code2:"TC",name:"Turks and Caicos Islands",id:218},{code2:"TV",name:"Tuvalu",id:219},{code2:"UG",name:"Uganda",id:220},{code2:"UA",name:"Ukraine",id:221},{code2:"AE",name:"United Arab Emirates",id:222},{code2:"GB",name:"United Kingdom",id:223},{code2:A,name:"United States",id:224},{code2:"UM",name:"United States Minor Outlying Islands",id:225},{code2:"UY",name:"Uruguay",id:226},{code2:"UZ",name:"Uzbekistan",id:227},{code2:"VU",name:"Vanuatu",id:228},{code2:"VA",name:"Vatican City State (Holy See)",id:229},{code2:"VE",name:"Venezuela",id:230},{code2:"VN",name:"Viet Nam",id:231},{code2:"VG",name:"Virgin Islands (British)",id:232},{code2:"VI",name:"Virgin Islands (U.S.)",id:233},{code2:"WF",name:"Wallis and Futuna Islands",id:234},{code2:"EH",name:"Western Sahara",id:235},{code2:"YE",name:"Yemen",id:236},{code2:"YU",name:"Yugoslavia",id:237},{code2:"DC",name:"The Democratic Republic of Congo",id:238},{code2:"ZM",name:"Zambia",id:239},{code2:"ZW",name:"Zimbabwe",id:240},{code2:"XE",name:"East Timor",id:241},{code2:"XJ",name:"Jersey",id:242},{code2:"XB",name:"St. Barthelemy",id:243},{code2:"XU",name:"St. Eustatius",id:244},{code2:"XC",name:"Canary Islands",id:245},{code2:"RS",name:"Serbia",id:246}],countriesByCode2:[]},screener:{page:{},pages:[]},mailingList:{},keyExecutive:{data:{}},homepage:{economicCalendar:[],stockNews:[],ipos:[],jobOpenings:[],topGainers:[],topLosers:[],mostActive:[],quotes:[]},fund:{topFunds:[],trendingStocks:[],funds:[],fund:{},fundStock:{},topFundsTotalCount:d,fundsTotalCount:d},feed:{newTickers:[],filterMapper:{financials:{metricType:a,feedEventTypes:["INCOME_STATEMENT","BALANCE_SHEET","CALENDAR_EARNINGS_DATE_UPDATED"],feedEventTypeIds:[o,t,p,q]},apps:{metricType:aY,feedEventTypes:[h,"APP_RANK_CATEGORY"],feedEventTypeIds:[b,f]},jobs:{metricType:aW,feedEventTypes:[h],feedEventTypeIds:[b]},calendars:{metricType:a,feedEventTypes:["CALENDAR_EARNINGS","CALENDAR_EARNINGS_EPS_UPDATED","CALENDAR_DIVIDEND"],feedEventTypeIds:[r,s,u]},social:{metricType:aV,feedEventTypes:[h],feedEventTypeIds:[b]},trends:{metricType:aZ,feedEventTypes:[h],feedEventTypeIds:[b]},stock_idea:{metricType:a,feedEventTypes:["STOCK_IDEA"],feedEventTypeIds:[c]},web_traffic:{metricType:aX,feedEventTypes:[h],feedEventTypeIds:[b]},insider_trading:{metricType:a,feedEventTypes:["INSIDER_TRADING"],feedEventTypeIds:[n]},twitter_mentions:{metricType:a,feedEventTypes:["TWITTER_MENTIONS"],feedEventTypeIds:[v]},hedge_funds:{metricType:a,feedEventTypes:["FUND_QUARTERLY_REPORT"],feedEventTypeIds:[w]}},filter:{tickers:[],datasets:["financials","apps","jobs","calendars","social","trends","web_traffic","insider_trading","hedge_funds"]},limit:x,offset:d,data:[]},earningsCalendar:{weeklyCalendar:[],dailyCalendar:[],popularCalendars:[{title:"S&P 500 Earnings Calendar",tagSlug:"sp-500"},{title:"Nasdaq Earnings Calendar",tagSlug:"nasdaq"},{title:"Dow Jones Earnings Calendar",tagSlug:"dow-jones"},{title:"Tech Earnings Calendar",tagSlug:"tech-stocks"},{title:"Banks Earnings Calendar",tagSlug:"bank-stocks"}]},dashboard:{},company:{topGainerLoserCompanies:[],trendingCompanies:[],topGrowthCompanies:[],patents:[],topDividendCompanies:[],dividendHistory:[],earningsCalendarHistory:[],dividendOverview:[],companies:[],funds:[],fundsTotalCount:d,companiesTotalCount:d,topGrowthCompaniesTotalCount:d,topDividendCompaniesTotalCount:d,companyOverview:{},companySocialSentiment:{},companyForecast:{},companyPrice:{},incomeStatement:{period:a},balanceSheet:{period:a},cashFlow:{period:a},highPotentialCompanies:[],highPotentialCompaniesSnapshotDates:[],graphs:{profitMargin:{period:a},stockForecast:{period:a},analystEstimate:{period:a},debtToAssets:{period:a},cashFlow:{period:a},twitterMentions:{period:a}},overview:{},ratios:{quarterly:{},annual:{}},incomeStatements:{quarterly:[],annual:[]},cashFlowStatements:{quarterly:[],annual:[]},calendar:{earningsCalendar:[],dividendCalendar:[],holidayCalendar:[]},balanceSheetStatements:{quarterly:[],annual:[]}},article:{articles:[],headerArticles:{interviews:[{title:"The Biggest Investment Potential: BGEO & HSBK",slug:"the-biggest-investment-potential-bgeo--hsbk",description:a,articleTypeId:c,publishedAt:"2023-04-13 15:29:00+00",articleCategoryId:b,imageUrl:"https:\u002F\u002Fi.ibb.co\u002F5LzHP5K\u002FMost-Attractive-Youtube-Thumbnail-Presentation-169-4.png",article_category:{type:l}},{title:" My 3 Biggest Positions Are PHM, NOC & CCI",slug:"-my-3-biggest-positions-are-phm-noc--cci",description:a,articleTypeId:c,publishedAt:"2023-04-09 07:33:00+00",articleCategoryId:b,imageUrl:"https:\u002F\u002Fi.ibb.co\u002FJCJ6n5F\u002FMost-Attractive-Youtube-Thumbnail-Presentation-169-3.png",article_category:{type:l}},{title:"My Best Performing Stock Is Gregg",slug:"my-best-performing-stock-is-gregg",description:a,articleTypeId:c,publishedAt:"2023-04-01 09:52:00+00",articleCategoryId:b,imageUrl:"https:\u002F\u002Fi.ibb.co\u002FMVBF6wN\u002FMost-Attractive-Youtube-Thumbnail-Presentation-169-2.png",article_category:{type:l}},{title:"Why To Invest In Founder-led Stocks",slug:"why-to-invest-in-founder-led-stocks",description:a,articleTypeId:c,publishedAt:"2023-03-29 09:55:00+00",articleCategoryId:b,imageUrl:"https:\u002F\u002Fi.ibb.co\u002FKs9KC5P\u002FBlue-Modern-Stock-Market-News-Youtube-Thumbnail.png",article_category:{type:l}}],alternativeData:[{title:" Exploring the Pros and Cons of Joining a Prop Trading Firm",slug:"-exploring-the-pros-and-cons-of-joining-a-prop-trading-firm",description:a,articleTypeId:c,publishedAt:"2023-07-14 14:02:00+00",articleCategoryId:e,imageUrl:"https:\u002F\u002Fi.ibb.co\u002FC1qC0sF\u002FBlue-Modern-Stock-Market-News-Youtube-Thumbnail-1.png",article_category:{type:m}},{title:"What Is A Net Worth And How Is It Calculated?",slug:"what-is-a-net-worth-and-how-is-it-calculated",description:a,articleTypeId:c,publishedAt:"2023-04-26 11:27:00+00",articleCategoryId:e,imageUrl:"https:\u002F\u002Fi.ibb.co\u002Fq1CDYvp\u002FBlue-Galaxy-Magnifying-Glass-Search-Bar-Twitter-Post-1.png",article_category:{type:m}},{title:"What Is A Company's MOAT?",slug:"what-is-a-companys-moat",description:a,articleTypeId:c,publishedAt:"2023-04-08 13:01:00+00",articleCategoryId:e,imageUrl:"https:\u002F\u002Fi.ibb.co\u002F6RZ6JDn\u002FBlue-Galaxy-Magnifying-Glass-Search-Bar-Twitter-Post.png",article_category:{type:m}},{title:"Top 5 Reasons Why Every Stock Investor Should Look at Insider Trading Information",slug:"top-5-reasons-why-every-stock-investor-should-look-at-insider-trading-information",description:a,articleTypeId:c,publishedAt:"2023-03-01 13:05:00+00",articleCategoryId:e,imageUrl:"https:\u002F\u002Fi.ibb.co\u002FKGc9gFt\u002FProfessional-Stock-Market-Going-Down-Twitter-Post.png",article_category:{type:m}}]},article:{}},analyst:{analyst:{},analysts:[],totalCount:d},i18n:{routeParams:{}},auth:{user:a,loggedIn:g,strategy:"local"}},serverRendered:B,routePath:"\u002Fstocks\u002FRDUS\u002Fearnings-call-transcripts\u002F56392",config:{axios:{browserBaseURL:"https:\u002F\u002Fapi.strike.market\u002Fapi"},app:{basePath:a_,assetsPath:a_,cdnURL:"https:\u002F\u002Fd3pvdr4j0h358p.cloudfront.net\u002F"}}}}(null,1,5,0,2,4,false,"ALTERNATIVE_METRIC",2022,3,2021,"interviews","alternative-data",6,7,8,9,10,11,12,13,14,16,20,"2021-06-18 00:29:52.078408+00",2023,"US",true,15,17,18,19,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,"FOLLOWERS_COUNT","JOB_OPENINGS_COUNT","WEB_TRAFFIC","APP_RANK","GOOGLE_TREND","\u002F"));</script><script src="https://d3pvdr4j0h358p.cloudfront.net/6cab9b3.js" defer="" async=""></script><script src="https://d3pvdr4j0h358p.cloudfront.net/6cec9d8.js" defer="" async=""></script><script src="https://d3pvdr4j0h358p.cloudfront.net/1eb99f0.js" defer="" async=""></script><script src="https://d3pvdr4j0h358p.cloudfront.net/0e1da10.js" defer="" async=""></script>   <ins class="adsbygoogle adsbygoogle-noablate" data-adsbygoogle-status="done" style="display: none !important;"><div id="aswift_0_host" style="border: none; height: 0px; width: 0px; margin: 0px; padding: 0px; position: relative; visibility: visible; background-color: transparent; display: inline-block;" tabindex="0" title="Advertisement" aria-label="Advertisement"><iframe id="aswift_0" name="aswift_0" style="left:0;position:absolute;top:0;border:0;width:undefinedpx;height:undefinedpx;" sandbox="allow-forms allow-popups allow-popups-to-escape-sandbox allow-same-origin allow-scripts allow-top-navigation-by-user-activation" frameborder="0" marginwidth="0" marginheight="0" vspace="0" hspace="0" allowtransparency="true" scrolling="no" src="https://googleads.g.doubleclick.net/pagead/ads?client=ca-pub-9608158334186947&amp;output=html&amp;adk=1812271804&amp;adf=3025194257&amp;lmt=1696806692&amp;plat=3%3A65536%2C4%3A65536%2C9%3A32776%2C16%3A8388608%2C17%3A32%2C24%3A32%2C25%3A32%2C30%3A1048576%2C32%3A32%2C41%3A32%2C42%3A32&amp;format=0x0&amp;url=https%3A%2F%2Fstrike.market%2Fstocks%2FRDUS%2Fearnings-call-transcripts%2F56392&amp;ea=0&amp;pra=5&amp;wgl=1&amp;easpi=0&amp;asro=0&amp;asiscm=1&amp;aslmt=0.4&amp;asamt=-1&amp;asedf=0&amp;asefa=1&amp;aseiel=1&amp;uach=WyJXaW5kb3dzIiwiMTUuMC4wIiwieDg2IiwiIiwiMTE3LjAuNTkzOC4xMzQiLFtdLDAsbnVsbCwiNjQiLFtbIkdvb2dsZSBDaHJvbWUiLCIxMTcuMC41OTM4LjEzNCJdLFsiTm90O0E9QnJhbmQiLCI4LjAuMC4wIl0sWyJDaHJvbWl1bSIsIjExNy4wLjU5MzguMTM0Il1dLDBd&amp;dt=1696806692008&amp;bpp=2&amp;bdt=72&amp;idt=26&amp;shv=r20231004&amp;mjsv=m202310040101&amp;ptt=9&amp;saldr=aa&amp;abxe=1&amp;cookie=ID%3D951edeb35ac1ddb1-22b541b182e400d2%3AT%3D1696806510%3ART%3D1696806511%3AS%3DALNI_Mbsinxii4ztjEisqVtABUrkshuwpA&amp;gpic=UID%3D00000d97d3596ecf%3AT%3D1696806510%3ART%3D1696806510%3AS%3DALNI_Mbqse9HQzvxL9l27akHLJS_qd4m8Q&amp;nras=1&amp;correlator=7181022407966&amp;frm=20&amp;pv=2&amp;ga_vid=1717068668.1696806644&amp;ga_sid=1696806692&amp;ga_hid=2088985539&amp;ga_fc=1&amp;u_tz=-240&amp;u_his=50&amp;u_h=1067&amp;u_w=1707&amp;u_ah=1019&amp;u_aw=1707&amp;u_cd=24&amp;u_sd=1.5&amp;dmc=8&amp;adx=-12245933&amp;ady=-12245933&amp;biw=1026&amp;bih=906&amp;scr_x=0&amp;scr_y=0&amp;eid=44759875%2C44759926%2C44759837%2C44798934%2C44804783%2C31078301%2C31078558&amp;oid=2&amp;pvsid=686352657790731&amp;tmod=1306274751&amp;uas=0&amp;nvt=1&amp;fsapi=1&amp;fc=1920&amp;brdim=10%2C10%2C10%2C10%2C1707%2C0%2C1050%2C1000%2C1036%2C906&amp;vis=1&amp;rsz=%7C%7Cs%7C&amp;abl=NS&amp;fu=32768&amp;bc=31&amp;ifi=1&amp;uci=a!1&amp;fsb=1&amp;dtd=32" data-google-container-id="a!1" data-load-complete="true"></iframe></div></ins></body><iframe id="google_esf" name="google_esf" src="https://googleads.g.doubleclick.net/pagead/html/r20231004/r20190131/zrt_lookup.html" style="display: none;"></iframe><ins class="adsbygoogle adsbygoogle-noablate" data-adsbygoogle-status="done" style="display: none !important; width: 100vw !important; height: 100vh !important; inset: 0px auto auto 0px !important; clear: none !important; float: none !important; margin: 0px !important; max-height: none !important; max-width: none !important; opacity: 1 !important; overflow: visible !important; padding: 0px !important; position: fixed !important; vertical-align: baseline !important; visibility: visible !important; z-index: 2147483647 !important; background: transparent !important;" aria-hidden="true" data-ad-status="filled" data-vignette-loaded="true"><div id="aswift_1_host" tabindex="0" title="Advertisement" aria-label="Advertisement" style="border: none !important; height: 100vh !important; width: 100vw !important; margin: 0px !important; padding: 0px !important; position: relative !important; visibility: visible !important; background-color: transparent !important; display: inline-block !important; inset: auto !important; clear: none !important; float: none !important; max-height: none !important; max-width: none !important; opacity: 1 !important; overflow: visible !important; vertical-align: baseline !important; z-index: auto !important;"><iframe id="aswift_1" name="aswift_1" style="width: 100vw !important; height: 100vh !important; inset: 0px auto auto 0px !important; position: absolute !important; clear: none !important; display: inline !important; float: none !important; margin: 0px !important; max-height: none !important; max-width: none !important; opacity: 1 !important; overflow: visible !important; padding: 0px !important; vertical-align: baseline !important; visibility: visible !important; z-index: auto !important;" sandbox="allow-forms allow-popups allow-popups-to-escape-sandbox allow-same-origin allow-scripts allow-top-navigation-by-user-activation" width="" height="" frameborder="0" marginwidth="0" marginheight="0" vspace="0" hspace="0" allowtransparency="true" scrolling="no" src="https://googleads.g.doubleclick.net/pagead/html/r20231004/r20110914/zrt_lookup.html?fsb=1#RS-0-&amp;adk=1812271808&amp;client=ca-pub-9608158334186947&amp;fa=8&amp;ifi=2&amp;uci=a!2&amp;xpc=wFGO9pqdNV&amp;p=https%3A//strike.market" data-google-container-id="a!2" data-google-query-id="CInDlsHJ54EDFZ670QQdsUsBmQ" data-load-complete="true"></iframe></div></ins></html>